SUPPLEMENT
FY2022 — Results booklet
FY2022PDF · 58 pages5.2 MB
for the year ended 30 June 2022
AUDITED
RESULTS
-- 1 of 58 --
NORMALISED PROFIT
FROM OPERATIONS
(R million)
2018
2019
2020
2021
2022
6 494
6 069
7 747
8 266
9 384
EMBEDDED VALUE
(R million)
2018
2019
2020
2021
2022
74 645
70 834
71 217
65 624
86 258
CORE NEW BUSINESS
API
(R million)
2018
2019
2020
2021
2022
20 409
19 173
18 329
16 137
21 710
GROSS INFLOWS
UNDER MANAGEMENT
(R million)
2018
2019
2020
2021
2022
162 043
154 833
139 062
125 554
172 168
-- 2 of 58 --
1
The Group delivered a strong operating performance from the established operations and
remained resilient in a challenging macro-economic environment. The organisation’s drive for
growth manifested through Discovery Bank and in the ongoing evolution of its global
healthcare model, notably with the establishment of Amplify Health. In addition, the Vitality
Shared-value business model continued to demonstrate its relevance and ability to deliver
value to clients and Discovery across all aspects of the value chain as well as to broader
society. This supports continued investment in the model.
The operating environment for the full year ended 30 June 2022 was characterised by two significant factors: Firstly, the evolution of
COVID-19, as the emergency phase of the pandemic has passed, with conditions in most markets normalising, except for Asia which was
affected by severe lockdowns and restrictions. Secondly, considerable geo-political polarisation and macro-economic volatility, caused by
a combination of the COVID-19 pandemic, Ukraine conflict, and supply-side constraints. This resulted in higher inflation, increased
interest rates as well as currency and market volatility.
In light of this, the Group focused on a pivot to growth based on three strategies:
(1) Achieving robust performance and strong competitive positioning of businesses within the South Africa (“SA”) Composite, United
Kingdom (“UK”) Composite and Vitality Global, by successfully navigating the latter stages of the COVID-19 period; continuing to
invest in the Vitality Shared-value business model; and ensuring excellent execution and operational delivery.
(2) Driving new business initiatives to scale, led by Discovery Bank and initiatives within Vitality Group, notably Amplify Health, and
streamlining some initiatives so the Group is well positioned for strong growth, and ensuring spend on new initiatives reverts to the
Group’s long-term guidance of 10% of operating profit.
(3) Ensuring capital and business strength and discipline with high levels of liquidity and solvency and a commensurate reduction in
the Group’s financial leverage ratio.
STRONG OPERATIONAL PERFORMANCE HIGHLIGHTS THE RESILIENCE AND
RELEVANCE OF THE MODEL IN A COMPLEX ENVIRONMENT
For the year ended 30 June 2022, normalised operating profit increased by 45% to R9 384 million and normalised headline earnings
increased by 71% to R5 816 million. Core new business annualised premium income (API) increased by 6% to R21 710 million, with
particularly strong growth from the SA and UK Composites, and persistency that continued to exceed expectations in all businesses.
Continued strong progress in Discovery Bank saw the investment in new initiatives at 18%1 of normalised operating profit, compared with
24% in the previous period.
Normalised headline earnings per share (basic) increased by 71% to 885.5 cents and headline earnings per share (basic) increased by 74%
to 792.4 cents, both positively impacted by mark-to-market foreign currency gains. Within headline earnings, the negative effect of higher
long-term interest rates in SA was partly offset by the benefit of higher long-term interest rates in the UK. A portion of the full benefit in
the UK, after hedge effects, was recognised as an increase in discretionary margins.
The Group continued to navigate the COVID-19 pandemic across its global operations in the reporting period, with mortality risk in SA
having had the largest impact on the prior year profit. The reporting period included the end of the Delta variant third wave of the
COVID-19 pandemic in SA and the highly infectious, but less virulent Omicron variant, for which the previously raised COVID-19 provisions
for the Group’s life insurance operations were adequate. As the emergency phase of the pandemic has passed, the focus has shifted to
incorporating the longer-term implications of COVID-19 and future mortality progression, resulting in significant overall strengthening of
the mortality and morbidity bases in the life insurance operations in the June 2022 actuarial review by R2.6 billion.
1 As a percentage of established and emerging normalised profit from operations
COMMENTARY
-- 3 of 58 --
2 Discovery audited results for the year ended 30 June 2022
In this context, the SA and UK Composites delivered strong growth in normalised operating profit and new business, while the
operating performance of Vitality Global reflected the specific dynamics of the impact of COVID-19 on the Asian markets. The
following table provides a summary of the performance:
Normalised
profit from
operations,
current period,
in ZAR million
% change
(Current
period vs
prior period)
Core new
business API*,
current
period, in
ZAR million
% change
(Current
period vs
prior period)
Discovery Health 3 600 5 7 292 20
Discovery Life 4 028 200 2 543 12
Discovery Invest 1 204 11 2 920 7
Discovery Insure (162) (165) 1 246 (3)
SA Composite (excluding new initiatives)2 8 679 41 14 257 15
VitalityHealth 1 328 39 1 738 27
VitalityLife 671 4 1 256 10
UK Composite (excluding new initiatives) 1 999 25 2 994 19
Vitality Group (Insurance and Vitality Health
International (VHI)) 473 13 1 398* 10*
Ping An Health Insurance (25% interest) 338 (18) 2 883 (15)
Vitality Global (excluding new initiatives) 811 (2) 4 281* (8)*
Discovery Bank (990)
10
(reduction in spend)
Other new initiatives (Excluding Bank)1 (1 115)
14
(increase in spend) 1 576 (25)
New initiatives (2 105) 2 1 576 (25)1
Normalised profit from operations2 9 384 45
Core new business API2 21 710 6
* Core new business API excludes Discovery Health (DH) take-on of new closed schemes and gross revenue for Vitality Group
1. Refer to normalised profit from operations regional disclosure for regional composition of new initiative spend; Core API for other new initiatives
includes Umbrella Funds, Discovery Insure commercial and VitalityInvest – new business was impacted by the lumpy nature of Umbrella Fund sales
which grew strongly in the prior period
2. Includes SA Vitality: normalised profit from operations includes R9 million (prior period: R43 million); core new business API includes R256 million
(prior period: R24 million)
COMMENTARY continued
-- 4 of 58 --
3
DRIVING NEW BUSINESS INITIATIVES TO SCALE AND STREAMLINING
SOME INTERESTS, SO NEW INITIATIVES SPEND REVERTS TO THE
GROUP’S LONG-TERM GUIDANCE OF 10% OF OPERATING PROFIT
The Group is emerging from a cycle of intense organic investment into new initiatives, dominated by the investment in Discovery
Bank, which has seen excellent high-quality growth over the period. The period saw increased investment in Vitality Health
International, particularly for the establishment of Amplify Health, as announced on 15 February 2022, and the build-out over the
year. There has also been continued investment in the other large-scale new initiatives, such as V1, the platform to scale the
globalisation of the Vitality Shared-value model.
Additionally, the Group streamlined some new initiatives with a focus on those businesses expected to generate significant value.
In addition to reviewing its stake in AIA Health in Australia, the Group decided to exit the UK investment market given the structural
change in market conditions, mainly driven by significant margin compression. Despite VitalityInvest making good progress over the
period, the decision was taken based on the time and resources needed to accumulate the necessary assets under management
(AUM) for the business to turn to profitability and the AUM needed to generate material long-term value for the Group.
CAPITAL AND BUSINESS STRENGTH AND DISCIPLINE WITH ROBUST
LIQUIDITY AND SOLVENCY
Discovery generated a strong return on opening embedded value (RoEV) of 14.8%, benefiting from particularly favourable lapse
experience and the impact of a significant strengthening of the future mortality and morbidity basis. Liquidity and solvency
remained robust across the Group, despite paying R3.7 billion in COVID-19 claims in the reporting period in SA, gross of reinsurance.
The financial leverage ratio improved to 23.8% , well below the internally set guidance threshold of 28%.
The overall resilience ensured continued focus on and progress in the market-specific strategies and objectives of the Group,
which are:
1. South Africa: To be the perfect composite model, number 1 in our chosen segments in every industry, and Discovery Bank
pivoting to growth as the composite-maker within SA.
2. United Kingdom: To have best-in-breed products across businesses and operating as a fully integrated composite business
with a seamless One Vitality client journey; and to have a successful entry into motor insurance.
3. Vitality Global (incorporating Vitality Group and Ping An Health Insurance): To be the foremost provider of health and
wellness intellectual property, powered by the right combination of technology and analytics – accelerating the growth of global
insurers by attracting and engaging clients.
-- 5 of 58 --
4 Discovery audited results for the year ended 30 June 2022
BUSINESS-SPECIFIC PERFORMANCE
South Africa
The SA composite’s normalised operating profit increased by 41% to R8 679 million and new business by 15% to R14 257 million,
excluding new initiatives. The results were driven by a strong recovery from Discovery Life, and robust performances from Discovery
Health and Discovery Invest, while Discovery Insure was negatively impacted by claims related to severe weather, combined with
considerable supply-side inflation related to the cost of repairing motor vehicles. Discovery Bank constitutes the largest investment
into new initiatives and invested further in product innovations and digital capabilities, as the Bank evolves into a composite-maker
in the retail Discovery ecosystem.
Discovery Bank’s operating loss for the financial year was R990 million, 10% lower than the previous financial year. The Bank
continues to expand its current client base, with 470 220 clients (331 000 in the prior period) and 1 023 790 accounts (versus
649 000 in June 2021), which represents a significant milestone for the Bank. Retail deposits grew by 30% to R10.6 billion and
advances grew 14% to R4.3 billion. New business volumes continued to be strong, achieving more than 800 average daily new-
to-Bank sales (vs 500 in June 2021), showing significant progress toward a medium-term target of 1 000 sales per day and
1 000 000 clients by 2026. The Bank has also continued to attract high quality clients, resulting in high levels of average non-
interest revenue (NIR) and a low credit loss ratio of 1.56%.
Discovery Bank
Discovery Health’s (DH) normalised operating profit increased by 5% to R3 600 million and core new business API increased by
20% to R7 292 million. Non-medical scheme retail products (FlexiCare, Gap Cover and Healthy Company) also continued to
demonstrate strong growth, with total lives increasing by 37% to c.263 000 lives and revenue increasing by 7% to R1 224 million.
Discovery Health Medical Scheme (DHMS) delivered an excellent performance: the high new business levels seen in the first half
of the financial year continued, with DHMS showing net growth of more than 24 000 lives over the full financial year, growing
DHMS market share to 57.6% of open medical scheme beneficiaries. DHMS’s new joiner profile has been healthier, with both a
lower average age and a lower chronic condition ratio than the rest of the open industry, boding favourably for existing members
and scheme sustainability. DHMS remains in a strong financial position, with an unaudited solvency of 36% as at June 2022.
DHMS’s pricing strategy continues to protect its members by balancing short-term affordability with long-term sustainability.
Considering the deferred contribution increase strategy, DHMS members paid lower contributions than the rest of the industry
in both 2021 and 2022; with contribution levels matched to expected future medical inflation.
Discovery Health
COMMENTARY continued
-- 6 of 58 --
5
Discovery Life’s (DL) results recovered strongly from the prior period, with normalised earnings of R4 028 million up 200%. This
was driven by positive overall experience, COVID-19 experience consistent with provision modelling, and prudent expense
management. New business increased by 12% to R2.5 billion, driven by strong Automatic Contribution Increases (ACIs) with the
DL new business margin at 5.3%. The embedded value (including Discovery Invest) increased by 10.5%, further highlighting the
strong positive operational experience, in particular good persistency offsetting a worse-than-expected morbidity claims
experience. Discovery Life paid R3.7 billion in COVID-19 claims, gross of reinsurance, in the reporting period, with all identified
individual life insurance COVID-19 claims sufficiently covered by the associated provision. The business has strengthened the
mortality and morbidity basis for future longer-term effects of COVID-19. The financial position remains robust with a solvency
ratio of 174% and strong internal liquidity buffers.
Discovery Life
Discovery Invest’s normalised operating profit increased by 11% to R1 204 million and new business increased 7% to R2 920 million.
Total assets under administration (AuA) grew by 4% to R122 billion, assets under management (AUM) increased by 7% to
R81.1 billion, and linked funds in Discovery funds remained high at 80%. Net flows increased by 2% to R5.75 billion, with growth
constrained by higher than anticipated guaranteed plan maturities and lower market levels over the second half of the reporting
period, resulting in a 4.6% reduction in AuA from December 2021 to June 2022. Discovery Invest recently launched Cogence, SA’s
first Shared-value Discretionary Fund Manager to drive better retirement outcomes. The partnership with BlackRock leverages
its Aladdin WealthTM Technology to manage the investment risk with Vitality managing the demographic risk.
Discovery Invest
Discovery Insure (DI) made an operating loss of R162 million, a 165% decrease from the prior year operating profit. The operating
loss was driven predominantly by adverse weather events including the April 2022 KwaZulu-Natal floods, which led to a
R66 million net impact, combined with motor parts inflation dramatically exceeding CPI. The result was further impacted by an
increase in power surge-related claims during the period. Gross written premium grew by 13% to R4 762 million, despite lower
new business levels, as DI was quick to implement strategic actions to manage the impact of the business experience, while also
improving the overall client risk profile.
Discovery Insure
-- 7 of 58 --
6 Discovery audited results for the year ended 30 June 2022
United Kingdom
The UK Composite’s normalised operating profit increased by 28% to £98.7 million (R1 999 million, up 25%) and new business by
22% to £148 million (R2 994 million, up 19%), excluding new initiatives. Earned premiums increased by 8% to £893 million
(R18 094 million, up 5%), while total lives covered increased by 12% to 1.56 million. The Group decided to exit the UK investment
market through VitalityInvest, despite its progress over the period, mainly driven by significant margin compression in the industry.
VitalityHealth’s (VH) normalised operating profit grew by 43% to £66 million (up 39% to R1 328 million). While claims increased
during the period, these remained below pre-COVID-19 levels and their severity and cost were less than expected. The result
also benefited from the acceleration of financial reinsurance repayments in the prior period. The sales performance over the
period was excellent, with new business increasing by 30% to £86 million (up 27% to R1 738 million). Standout areas included
the D2B strategy, with the channel delivering 61% growth in total, and the direct channel, which continued to perform strongly
with 15% growth. Earned premiums grew by 9% to £560 million (R11 344 million, up 6%) driven by strong retention levels, and
total lives grew by 15% to 839 000. After new business acquisition costs and investment in developing the business, VH generated
£32 million (R648 million) cash. VH continues to transform the way that healthcare is delivered, as seen by the increase in the
use of primary care services, and the growth in scale and utilisation of digitised services.
VitalityHealth
VitalityLife’s (VL) normalised operating profit grew by 7% to £33.1 million (R671 million, up 4%). New business increased by 13%
to £62 million (R1 256 million, up 10%), with VL improving its position to fifth in market share for new business for Q1 2022. The
continued strong retention performance, following strategic interventions in prior years, was key in delivering 7% higher earned
premiums, to £333 million (up 4% to R6 750 million), while lives covered grew by 9% to 722 000.
A significant milestone in the period was reaching agreement with Prudential on the Part VII transfer of the VitalityLife book,
currently written on the Prudential balance sheet. The agreement effects an indefinite delay period to complete the Part VII
transfer and results in reduced liquidity, matching and capital risk, as well as lower operational complexity with improved overall
commercial terms.
VitalityLife
Vitality Global
Ping An Health Insurance’s (PAH) profit from operations, represented by the Group’s share of after-tax operating profit less
Discovery’s costs to support the business, was down by 18% to R338 million. PAH’s pre-tax operating profit, excluding investment
income and gains, increased by 30%, highlighting the strong operating performance over the period, curtailed by the decline in
the China equity market. Total new business premiums reduced by 15% to R11.5 billion, given the restructured co-operation
with Ping An Life, as described in the Group’s interim reporting. However, new business premiums on PAH’s own insurance
licence increased by 6% to R8.9 billion, following increased development of PAH’s own sales channels. PAH is delivering faster
premium growth than the overall industry and the business has reached considerable scale and continues to be one of the most
profitable and fastest growing insurers in the country, insuring over 28 million lives, with a comprehensive solvency ratio
at 277.1%.
Ping An Health Insurance
COMMENTARY continued
-- 8 of 58 --
7
Vitality Group’s (VG) profit increased by 15% to US$31 million (R473 million, up 13%). Earnings growth was impacted as the prior
period benefited from a forex hedge gain, which was not repeated, offset in this period by income related to the delivery of an
initial component of Vitality intellectual property, related to the Amplify Health transaction. Earnings were also impacted by
weaker Vitality-integrated sales in some key Asian markets, adversely impacted by COVID-19 lockdowns in the current period.
Revenue growth remained resilient, with fee income growing 22% to US$100.4 million (R1.5 billion) and insurance partners’
Vitality-integrated premiums growing by 10% to US$1.4 billion (R21.7 billion). The period also saw Vitality expand to 35 markets
by the end of the reporting period, with Vitality membership from insurance partners increasing 25% to 3 million. Sumitomo Life
Vitality in Japan reached a milestone of 1 million Vitality-linked policies sold since launching in 2018.
There has been significant investment within new initiatives in Vitality Health International, with a focus on expanding the
Group’s global health solutions business and maintaining global leadership in behaviourally led solutions. The largest investment
over the period was into the Amplify Health joint venture with AIA, offering digital health solutions across Asia-Pacific. Additionally,
the business launched shared-value health insurance products, which incorporate Vitality, to employer groups operating in
multiple African countries beyond South Africa.
Vitality Group
Prospects and dividend
Discovery’s business model has proven to be highly relevant during the COVID-19 pandemic, with robust underlying growth trends
continuing in most parts of the business. The Group is capitalising on its growth opportunities while ensuring operational resilience
despite the challenging macro environment. The effect of rising inflation and interest rates globally, together with continued
currency volatility, is expected to remain a feature of the reported results.
During the period, Discovery made a capital contribution to PAH of R1.5 billion. While this was initially funded by way of a bridge
facility and internal resources, as previously reported, Discovery still anticipates raising a specific quantum of equity capital for this
purpose in line with the disciplined framework of its capital plan.
While the Group’s capital position remains robust, in light of the uncertain future impact of COVID-19 and the volatile global macro-
economic environment, the Discovery Board has decided to retain its prior stated position and has decided not to declare an
ordinary final dividend for the year ended 30 June 2022. The reintroduction of an ordinary dividend will be considered on an
ongoing basis.
Notes to analysts
Any forecast financial information contained in this announcement has not been reviewed or reported on by the Company's
external auditors.
Discovery has published supplemental unaudited information on the website. For this and other results information, visit
https://www.discovery.co.za/corporate/investor-relations and go to Financial and annual reports.
On behalf of the Board
ME Tucker A Gore
Chairperson Group Chief Executive
Sandton
6 September 2022
-- 9 of 58 --
8 Discovery audited results for the year ended 30 June 2022
-- 10 of 58 --
9
STATEMENT OF FINANCIAL POSITION
at 30 June 2022
R million
Group
Year ended
June
2022
Audited
Group
Year ended
June
2021
Audited
Assets
Goodwill 4 912 4 879
Intangible assets 6 539 6 371
Property and equipment 3 811 4 188
Assets arising from insurance contracts 56 645 50 483
Deferred acquisition costs 640 585
Assets arising from contracts with customers 1 549 1 248
Investment in equity-accounted investees 6 008 3 459
Deferred tax asset 4 455 3 948
Financial assets
– Loans and advances to customers at amortised cost 3 944 3 361
– Investments at amortised cost 7 161 5 604
– Investments at fair value through profit or loss 141 494 130 937
– Derivative financial instruments at fair value through profit or loss 276 249
Insurance receivables, contract receivables and other receivables 13 113 10 533
Non-current assets held for sale 171 –
Current tax asset 220 391
Reinsurance contracts 511 445
Cash and cash equivalents 19 775 20 013
TOTAL ASSETS 271 224 246 694
Equity
Capital and reserves
Ordinary share capital and share premium 10 178 10 151
Perpetual preference share capital 779 779
Other reserves 3 621 1 935
Retained earnings 38 972 33 550
Equity 53 550 46 415
Non-controlling interest 5 4
TOTAL EQUITY 53 555 46 419
Liabilities
Liabilities arising from insurance contracts 109 200 100 977
Liabilities arising from reinsurance contracts 13 192 12 525
Deferred tax liability 9 335 8 814
Contract liabilities to customers 944 776
Financial liabilities
– Borrowings at amortised cost 20 584 19 493
– Other payables 15 123 14 904
– Deposits from customers 10 881 8 985
– Investment contracts at fair value through profit or loss 37 361 32 291
– Derivative financial instruments at fair value through profit or loss 202 826
Employee benefits 320 315
Current tax liability 527 369
TOTAL LIABILITIES 217 669 200 275
TOTAL EQUITY AND LIABILITIES 271 224 246 694
-- 11 of 58 --
10 Discovery audited results for the year ended 30 June 2022
GROUP INCOME STATEMENT
for the year ended 30 June 2022
R million
Group
Year ended
June
2022
Audited
Group
Year ended
June
2021
Audited
%
Change
Insurance premium revenue 58 782 55 935
Reinsurance premiums (8 262) (7 729)
Accelerated reinsurance premiums – (823)
Net insurance premium revenue 50 520 47 383 7
Fee income from administration businesses 12 752 11 700
Vitality income 3 495 3 340
Net banking fee and commission income 645 480 34
Banking fee and commission income 853 633
Banking fee and commission expense (208) (153)
Net bank interest and similar income 318 241 32
Bank interest and similar income using the effective interest rate 811 627
Bank interest and similar expense using the effective interest rate (493) (386)
Investment income using the effective interest rate method 296 280
Net fair value (losses)/gains on financial assets at fair value through profit or loss (1 825) 11 891
Other income 1 341 1 372
Receipts arising from reinsurance contracts – 500
Net income 67 542 77 187 (12)
Net claims and policyholders’ benefits (30 900) (28 178) (10)
Claims and policyholders' benefits (38 207) (33 972)
Insurance claims recovered from reinsurers 7 218 5 794
Recapture of reinsurance 89 –
Acquisition costs (4 774) (5 033)
Marketing and administration expenses (25 209) (22 679)
Amortisation of intangibles from business combinations (59) (66)
Expected credit losses (67) (271)
Recovery of expenses from reinsurers 2 859 2 773
Net transfer to/from assets and liabilities under insurance contracts (1 494) (14 795)
– change in assets arising from insurance contracts 5 786 545
– change in assets arising from reinsurance contracts 63 56
– change in liabilities arising from insurance contracts (6 935) (17 941)
– change in liabilities arising from reinsurance contracts (577) 1 755
– economic assumption adjustments net of discretionary margins 169 790
Fair value adjustment to liabilities under investment contracts (40) (3 634)
Profit from operations 7 858 5 304 48
Finance costs (1 658) (1 648)
Foreign exchange gains/(losses) 155 (389)
Gain on dilution and disposal of equity-accounted investments 33 554
Reversal of impairment/(Impairment) of equity-accounted investments 134 (149)
Share of net profits from equity-accounted investments 422 523
Profit before tax 6 944 4 195 66
Income tax expense (1 465) (975) (50)
Profit for the year 5 479 3 220 70
Profit attributable to:
– ordinary shareholders 5 422 3 157
– preference shareholders 56 63
– non-controlling interest 1 *
5 479 3 220 70
Earnings per share for profit attributable to ordinary shareholders of the
company during the year (cents):
– basic 825.5 480.7 72
– diluted 817.8 475.4 72
* Amount is less than R500 000.
-- 12 of 58 --
11
GROUP STATEMENT OF OTHER COMPREHENSIVE INCOME
for the year ended 30 June 2022
R million
Group
Year ended
June
2022
Audited
Group
Year ended
June
2021
Audited
Profit for the year 5 479 3 220
Items that are or may be reclassified subsequently to profit or loss:
Currency translation differences 467 (1 576)
Cash flow hedges 309 260
– unrealised gains 322 360
– tax on unrealised gains (2) (25)
– gains recycled to profit or loss (10) (90)
– tax on recycled gains (1) 15
Share of other comprehensive income from equity-accounted investments 601 (312)
– change in fair value of debt instruments at fair value through other comprehensive income 17 15
– currency translation differences 584 (327)
Other comprehensive income/(losses) for the year, net of tax 1 377 (1 628)
Total comprehensive income for the year 6 856 1 592
Attributable to:
– ordinary shareholders 6 799 1 529
– preference shareholders 56 63
– non-controlling interest 1 *
Total comprehensive income for the year 6 856 1 592
* Amount is less than R500 000.
-- 13 of 58 --
12 Discovery audited results for the year ended 30 June 2022
GROUP STATEMENT OF CHANGES IN EQUITY
for the year ended 30 June 2022
Attributable to equity holders of the Company
R million
Share
capital
and share
premium
Preference
share
capital
Share-based
payment
reserve
Investment
reserve1
Year ended 30 June 2022
At beginning of the year 10 151 779 489 18
Total comprehensive income for the year – 56 – 17
Profit for the year – 56 – –
Other comprehensive income – – – 17
Transactions with owners 27 (56) 309 –
Share issue 443 – – –
Increase in treasury shares (443) – – –
Delivery of treasury shares 27 – (17) –
Employee share option schemes:
– Value of employee services – – 326 –
Dividends paid to preference shareholders – (56) – –
At end of the year 10 178 779 798 35
Year ended 30 June 2021
At beginning of the year 10 148 779 195 3
Total comprehensive income for the year – 63 – 15
Profit for the year – 63 – –
Other comprehensive income/(loss) – – – 15
Transactions with owners 3 (63) 294 –
Share issue 907 – – –
Increase in treasury shares (907) – – –
Delivery of treasury shares 3 – (36) –
Employee share option schemes:
– Value of employee services – – 330 –
Dividends paid to preference shareholders – (63) – –
At end of the year 10 151 779 489 18
1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income (FVOCI) and those debt
instruments measured at FVOCI, in terms of IFRS 9 Financial Instruments.
* Amount is less than R500 000.
-- 14 of 58 --
13
Attributable to equity holders of the Company
Foreign
currency
translation
reserve
Hedging
reserve
Retained
earnings Total
Non-
controlling
interest Total
1 772 (344) 33 550 46 415 4 46 419
1 051 309 5 422 6 855 1 6 856
– – 5 422 5 478 1 5 479
1 051 309 – 1 377 – 1 377
– – – 280 – 280
– – – 443 – 443
– – – (443) – (443)
– – – 10 – 10
– – – 326 – 326
– – – (56) – (56)
2 823 (35) 38 972 53 550 5 53 555
3 675 (604) 30 353 44 549 4 44 553
(1 903) 260 3 157 1 592 * 1 592
– – 3 157 3 220 * 3 220
(1 903) 260 – (1 628) – (1 628)
– – 40 274 – 274
– – – 907 – 907
– – – (907) – (907)
– – 40 7 – 7
– – – 330 – 330
– – – (63) – (63)
1 772 (344) 33 550 46 415 4 46 419
-- 15 of 58 --
14 Discovery audited results for the year ended 30 June 2022
GROUP STATEMENT OF CASH FLOWS
for the year ended 30 June 2022
R million
Group
Year ended
June
2022
Audited
Group
Year ended
June
2021
Audited
Cash flow from operating activities 3 597 10 407
Cash generated by operations 18 475 19 485
Purchase of investments held to back policyholder liabilities (56 588) (54 661)
Proceeds from disposal of investments held to back policyholder liabilities 38 411 38 709
Working capital changes 2 468 6 972
2 766 10 505
Dividends received 600 303
Interest received 2 824 2 513
Interest paid (1 412) (1 197)
Taxation paid (1 181) (1 717)
Cash flow from investing activities (4 704) (6 740)
Purchase of financial assets (32 878) (32 569)
Proceeds from disposal of financial assets 31 482 27 828
Purchase of property and equipment (275) (277)
Proceeds from disposal of property and equipment 25 21
Purchase of software and other intangible assets (1 567) (1 587)
Proceeds from disposal of software and other intangible assets 2 –
Acquisition of business net of cash – (25)
Additional investment in equity-accounted investments (1 593) (240)
Dividends from equity-accounted investments 100 109
Cash flow from financing activities 518 (590)
Dividends paid to preference shareholders (56) (63)
Proceeds from borrowings 3 261 1 839
Repayment of borrowings (2 687) (2 366)
Net (decrease)/ increase in cash and cash equivalents (589) 3 077
Cash and cash equivalents at beginning of the year 20 013 17 909
Exchange gains/(losses) on cash and cash equivalents 195 (973)
Cash and cash equivalents including bank overdraft at end of the year 19 619 20 013
Reconciliation to Statement of Financial Position
Cash and cash equivalents 19 775 20 013
Bank overdraft included in borrowings at amortised cost (156) –
Cash and cash equivalents at end of the year 19 619 20 013
-- 16 of 58 --
15
FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS
The Group’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has three
levels that reflect the significance of the inputs used in measuring fair value. These are as follows:
Level 1 includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical financial
instruments. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or
regulatory agency and those prices represent actual and regularly occurring market transactions on an arm’s length basis.
Level 2 includes financial instruments that are valued using techniques based significantly on observable market data. Instruments
in this category are valued using:
(a) quoted prices for similar instruments or identical instruments in markets which are not considered to be active; or
(b) valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on
observable market data.
Level 3 includes financial instruments that are valued using valuation techniques that incorporate information other than
observable market data and where at least one input (which could have a significant effect on instruments’ valuation) cannot be
based on observable market data.
R million (audited)
30 June 2022
Level 1 Level 2 Level 3 Total
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 54 271 3 677 – 57 948
– Debt portfolios 46 672 920 – 47 592
– Money market portfolios1 – 14 680 – 14 680
– Multi-asset portfolios1 – 21 274 – 21 274
Derivative financial instruments at fair value:
– used as cash flow hedges – 17 – 17
– not designated as hedging instruments – 259 – 259
Total financial assets 100 943 40 827 – 141 770
Non-Financial Assets
Non-current assets held of sale – – 171 171
Total non-financial assets – – 171 171
Financial liabilities
Investment contracts at fair value through profit or loss – 37 361 – 37 361
Derivative financial instruments at fair value:
– used as cash flow hedges – 56 – 56
– not designated as hedging instruments – 146 – 146
Total financial liabilities – 37 563 – 37 563
1 During the year under review, management had reassessed the observability of significant inputs into fair value determination of money markets and,
multi-asset portfolios. Management determined these are classified at level2. The prior period was restated accordingly.
There were no transfers between level 1 and 2 during the current financial period.
ADDITIONAL DISCLOSURE
at 30 June 2022
-- 17 of 58 --
16 Discovery audited results for the year ended 30 June 2022
FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS continued
R million (audited)
Restated
30 June 2021
Level 1 Level 2 Level 3 Total
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 40 530 2 832 – 43 362
– Debt portfolios 34 845 1 640 – 36 485
– Money market portfolios – 17 253 – 17 253
– Multi-asset portfolios – 33 837 – 33 837
Derivative financial instruments at fair value:
– used as cash flow hedges – 28 – 28
– not designated as hedging instruments – 221 – 221
Total financial assets 75 375 55 811 – 131 186
Financial liabilities – not designated as
hedging instruments
Investment contracts at fair value through profit and loss – 32 291 – 32 291
Derivative financial instruments at fair value:
– used as cash flow hedges – 461 – 461
– not designated as hedging instruments – 365 – 365
Total financial liabilities – 33 117 – 33 117
Specific valuation techniques used to value financial instruments in level 2
❚ Discovery has invested in equity linked notes offered by international banks in order to back certain unit-linked contract
liabilities. The calculation of the daily value of the equity linked investments is performed by the provider of the note. Discovery
has procedures in place to ensure that these prices are correct. Aside from the daily reasonableness checks versus similar funds
and movement since the prior day’s price, the fund values are calculated with reference to a specific formula or index, disclosed
to the policyholders, which is recalculated by Discovery in order to verify that if the price provided by the provider is correct.
❚ If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange traded financial
instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques including the use
of recent arm’s length market transactions, reference to the current fair value of another instrument that is substantially the
same, discounted cash flow techniques, option pricing models or other valuation techniques that provide a reliable estimate of
prices obtained in actual market transactions.
❚ The fair value of the hedged derivatives is calculated as follows:
(a) The fair value of call options is calculated on a Black-Scholes model.
(b) The fair value of the return swaps is calculated by discounting the future cash flows of the instruments.
(c) The fair value of interest rate swaps is calculated as the present value of the estimated future cash flows based on observable
yield curves.
ADDITIONAL DISCLOSURE continued
at 30 June 2022
-- 18 of 58 --
17
EXCHANGE RATES USED IN THE PREPARATION OF THESE RESULTS
USD GBP RMB
30 June 2022
– Average 15.22 20.25 2.35
– Closing 16.47 20.00 2.46
30 June 2021
– Average 15.42 20.74 2.32
– Closing 14.28 19.74 2.21
ADDITIONAL DISCLOSURE continued
at 30 June 2022
-- 19 of 58 --
18 Discovery audited results for the year ended 30 June 2022
R million
SA
Health
SA
Life
SA
Invest
Income statement
Insurance premium revenue 189 15 041 14 499
Reinsurance premiums – (3 523) –
Net insurance premium revenue 189 11 518 14 499
Fee income from administration businesses 7 910 – 2 834
Vitality income – – –
Net banking fee and commission income – – –
Banking fee and commission income4 – – –
Banking fee and commission expense – – –
Net bank interest and similar income – – –
Bank interest and similar income using the effective interest rate – – –
Bank interest and similar expense using the effective interest rate – – –
Investment income earned on assets backing policyholder liabilities – 3 –
Net fair value gains/(losses) on financial assets at fair value through profit or loss 10 485 913
Other income 1 241 12 –
Finance charge on negative reserve funding – – –
Inter-segment funding1 – (628) 628
Net income 9 350 11 390 18 874
Net claims and policyholders’ benefits (49) (9 222) (12 260)
Claims and policyholders' benefits (49) (14 013) (12 260)
Insurance claims recovered from reinsurers – 4 791 –
Recapture of reinsurance – – –
Acquisition costs (27) (1 605) (1 144)
Expected credit losses – – –
Marketing and administration expenses
– depreciation and amortisation (106) (7) (11)
– derecognition of intangible assets and property and equipment – – –
– other expenses (5 568) (2 147) (1 156)
Recovery of expenses from reinsurers – – –
Transfer from assets/liabilities under insurance contracts
– change in assets arising from insurance contracts – 5 299 –
– change in assets arising from reinsurance contracts – 11 –
– change in liabilities arising from insurance contracts – 662 (3 247)
– change in liabilities arising from reinsurance contracts – (351) –
Fair value adjustment to liabilities under investment contracts – (2) 148
Share of net profits from equity-accounted investments – – –
Reversal of impairment of equity accounted investment – – –
Normalised profit/(loss) from operations 3 600 4 028 1 204
Economic assumptions adjustments net of discretionary margins and interest rate derivative – (651) –
Economic assumptions adjustments net of discretionary margins – (651) –
Fair value losses on VitalityLife interest rate derivative – – –
Investment income earned on shareholder investments and cash 37 11 38
Intercompany investment income – – –
Net fair value gains/(losses) on financial assets at fair value through profit or loss – 51 27
Gains from dilution of equity accounted investments – – –
Initial expenses related to Prudential Book transfer – – –
Covid-19 vaccination programme – – –
Amortisation of intangibles from business combinations – – –
Market rentals related to Head Office building adjusted for finance costs and depreciation – – –
Finance costs5 (1) 25 –
Intercompany finance costs (297) – –
Foreign exchange gains 4 25 37
Profit before tax 3 343 3 489 1 306
Income tax expense (951) (718) (438)
Profit for the year 2 392 2 771 868
1 The inter-segment funding of R628 million reflects a notional allocation of interest earned on the negative reserve backing policyholders' funds of
guaranteed investment products and hence is transferred to Discovery Invest.
2 This segment relates to SA Insure - Personal lines.
3 The segment information is presented on the same basis as reported to the Chief Executive Officers of the reportable segments. The segment total is then
adjusted for accounting reclassifications and entries required to produce IFRS compliant results. These adjustments include the following:
– The VitalityLife results, for business written on the Prudential Assurance Company license, are reclassified to account for the contractual arrangement
as a reinsurance contract under IFRS 4.
– Unit trusts which the Group controls in terms of IFRS 10 are consolidated into Discovery's results for IFRS purposes. The IFRS reporting adjustments include
the effects of consolidating the unit trusts into Discovery's results, effectively being the income and expenses relating to units held by third parties.
– The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments.
SEGMENTAL INFORMATION
for the year ended 30 June 2022
-- 20 of 58 --
19
SA
Insure2
SA
Vitality
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS reporting
adjustments 3
IFRS
total
4 657 – – 11 299 6 750 7 035 59 470 (688) 58 782
(103) – – (1 556) (3 600) (168) (8 950) 688 (8 262)
4 554 – – 9 743 3 150 6 867 50 520 – 50 520
15 – – 30 – 1 975 12 764 (12) 12 752
– 2 338 – 392 227 538 3 495 – 3 495
– – 633 – – 12 645 – 645
– – 853 – – – 853 – 853
– – (220) – – 12 (208) – (208)
– – 318 – – – 318 – 318
– – 811 – – – 811 – 811
– – (493) – – – (493) – (493)
118 – – 9 27 7 164 (164) –
1 1 – (52) (1 390) (1 195) (1 227) (598) (1 825)
– – – 32 – 56 1 341 – 1 341
– – – – 1 368 – 1 368 (1 368) –
– – – – – – – – –
4 688 2 339 951 10 154 3 382 8 260 69 388 (2 142) 67 246
(3 029) – – (4 331) (877) (1 132) (30 900) – (30 900)
(3 151) – – (5 652) (2 231) (1 346) (38 702) 495 (38 207)
122 – – 1 321 1 265 214 7 713 (495) 7 218
– – – – 89 – 89 – 89
(702) (111) – (963) (1 884) 294 (6 142) 1 368 (4 774)
– – (67) – – – (67) – (67)
(60) (12) (277) (458) (63) (739) (1 733) (169) (1 902)
(18) – – (1) (14) (17) (50) – (50)
(988) (2 207) (1 597) (4 091) (2 047) (3 032) (22 833) (424) (23 257)
– – – 1 041 1 818 – 2 859 – 2 859
– – – – 3 606 (101) 8 804 (3 018) 5 786
1 – – 40 11 1 64 (1) 63
(41) – – (65) (17) (4 488) (7 196) 261 (6 935)
– – – – (3 244) – (3 595) 3 018 (577)
– – – – – 42 188 (228) (40)
(13) – – 2 – 474 463 (41) 422
– – – – – 134 134 – 134
(162) 9 (990) 1 328 671 (304) 9 384 (1 376) 8 008
– – – – 567 – (84) 253 169
– – – – 820 – 169 – 169
– – – – (253) – (253) 253 –
– 28 – – 8 18 140 156 296
– – – – 5 913 918 (918) –
– – – – (454) (1) (377) 377 –
19 – – – – 14 33 – 33
– – – – (182) – (182) 182 –
– – – – – (157) (157) 157 –
(41) – – – – (59) (100) 41 (59)
– – – – – (158) (158) 158 –
– – – (6) (104) (1 290) (1 376) (282) (1 658)
– – – (4) (230) (396) (927) 927 –
– – – – – 89 155 – 155
(184) 37 (990) 1 318 281 (1 331) 7 269 (325) 6 944
43 (30) 218 (285) 224 147 (1 790) 325 (1 465)
(141) 7 (772) 1 033 505 (1 184) 5 479 – 5 479
4 The banking fee and commission income consists of R389 million revenue which passes over time and interchange revenue of R464 million is recognised at a point
in time.
5 Finance costs in Discovery Life includes a reversal of interest payable to the South African Revenue Services provided for in the prior year.
-- 21 of 58 --
20 Discovery audited results for the year ended 30 June 2022
R million
SA
Health
SA
Life
SA
Invest
Income statement
Insurance premium revenue 294 13 711 14 824
Reinsurance premiums 1 (3 262) –
Accelerated reinsurance repayment – – –
Net insurance premium revenue 295 10 449 14 824
Fee income from administration businesses 7 540 – 2 401
Vitality income – – –
Net banking fee and commission income – – –
Banking fee and commission income4 – – –
Banking fee and commission expense – – –
Net bank interest and similar income – – –
Bank interest and similar income using the effective interest rate – – –
Bank interest and similar expense using the effective interest rate – – –
Investment income earned on assets backing policyholder liabilities – 10 –
Net fair value gains/(losses) on financial assets at fair value through profit or loss 6 637 9 172
Other income 968 3 –
Finance charge on negative reserve funding – – –
Inter-segment funding1 – (714) 714
Receipts arising from reinsurance contracts – 500 –
Net income 8 809 10 885 27 111
Net claims and policyholders' benefits (129) (8 113) (12 252)
Claims and policyholders' benefits (129) (11 949) (12 252)
Insurance claims recovered from reinsurers – 3 836 –
Acquisition costs (40) (1 540) (1 056)
Expected credit losses – – –
Marketing and administration expenses
– depreciation and amortisation (118) (7) (11)
– derecognition of intangible assets and property and equipment (26) – –
– impairment of intangible assets (15) – –
– other expenses (5 058) (2 027) (1 031)
Recovery of expenses from reinsurers – – –
Transfer from assets/liabilities under insurance contracts
– change in assets arising from insurance contracts – 3 433 –
– change in assets arising from reinsurance contracts – 33 –
– change in liabilities arising from insurance contracts – (206) (11 054)
– change in liabilities arising from reinsurance contracts – (1 115) –
Fair value adjustment to liabilities under investment contracts – (2) (623)
Share of net profits from equity-accounted investments – – –
Impairment of equity accounted investment – – –
Normalised profit/(loss) from operations 3 423 1 341 1 084
Economic assumptions adjustments net of discretionary margins and interest rate derivative – (411) –
Economic assumptions adjustments net of discretionary margins – (411) –
Fair value losses on VitalityLife interest rate derivative – – –
Investment income earned on shareholder investments and cash 39 14 40
Intercompany investment income – – –
Net fair value gains/(losses) on financial assets at fair value through profit or loss – 138 (28)
Restructuring costs – – –
Gains from dilution of equity accounted investments – – –
Initial expenses related to Prudential Book transfer – – –
Transaction costs related to VitalityLife interest rate derivatives – – –
Covid-19 vaccination programme – – –
Amortisation of intangibles from business combinations – – –
Market rentals related to Head Office building adjusted for finance costs and depreciation – – –
Finance costs5 (1) (26) –
Intercompany finance costs (268) – –
Foreign exchange (losses)/gains (6) 3 (25)
Profit before tax 3 187 1 059 1 071
Income tax expense (894) (364) (331)
Profit for the year 2 293 695 740
1 The inter-segment funding of R714 million reflects a notional allocation of interest earned on the negative reserve backing policyholders’ funds of
guaranteed investment products and hence is transferred to Discovery Invest.
2 This segment relates to SA Insure – Personal lines.
3 The segment information is presented on the same basis as reported to the Chief Executive Officers of the reportable segments. The segment total is then
adjusted for accounting reclassifications and entries required to produce IFRS compliant results. These adjustments include the following:
– The VitalityLife results, for business written on the Prudential Assurance Company license, are reclassified to account for the contractual arrangement as
a reinsurance contract under IFRS 4.
– Unit trusts which the Group controls in terms of IFRS 10 are consolidated into Discovery’s results for IFRS purposes. The IFRS reporting adjustments include
the effects of consolidating the unit trusts into Discovery’s results, effectively being the income and expenses relating to units held by third parties.
– The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments.
SEGMENTAL INFORMATION continued
for the year ended 30 June 2021
-- 22 of 58 --
21
SA
Insure2
SA
Vitality
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS reporting
adjustments3
IFRS
total
4 091 – – 11 075 6 466 6 351 56 812 (877) 55 935
(66) – – (1 839) (3 354) (86) (8 606) 877 (7 729)
– – – (823) – – (823) – (823)
4 025 – – 8 413 3 112 6 265 47 383 – 47 383
16 – 2 28 – 1 724 11 711 (11) 11 700
– 2 295 21 240 230 554 3 340 – 3 340
– – 464 – – 16 480 – 480
– – 633 – – – 633 – 633
– – (169) – – 16 (153) – (153)
– – 214 – – – 214 27 241
– – 627 – – – 627 – 627
– – (413) – – – (413) 27 (386)
111 – – – 9 9 139 (139) –
14 – 83 29 (792) 1 358 10 507 1 384 11 891
– – 312 60 – 10 1 353 19 1 372
– – – – 769 – 769 (769) –
– – – – – – – – –
– – – – – – 500 – 500
4 166 2 295 1 096 8 770 3 328 9 936 76 396 511 76 907
(2 270) – – (3 894) (837) (683) (28 178) – (28 178)
(2 269) – – (5 219) (1 962) (761) (34 541) 569 (33 972)
(1) – – 1 325 1 125 78 6 363 (569) 5 794
(599) (61) – (942) (1 719) 174 (5 783) 750 (5 033)
– – (271) – – – (271) – (271)
(70) (13) (246) (447) (57) (669) (1 638) (210) (1 848)
(6) – – – (18) (50) – (50)
– (1) – (5) – (40) (61) – (61)
(937) (2 177) (1 673) (3 297) (1 831) (2 598) (20 629) (91) (20 720)
– – – 912 1 861 – 2 773 – 2 773
– – – – (6 143) 76 (2 634) 3 179 545
– – 13 10 – 56 – 56
(47) – – (155) (17) (6 436) (17 915) (26) (17 941)
– – – – 6 049 – 4 934 (3 179) 1 755
– – – – – (255) (880) (2 754) (3 634)
13 – – (2) – 512 523 – 523
– – – – – (149) (149) – (149)
250 43 (1 094) 953 644 (150) 6 494 (1 820) 4 674
– – – – (108) – (519) 1 309 790
– – – – 1 201 – 790 – 790
– – – – (1 309) – (1 309) 1 309 –
– 39 – – 3 14 149 131 280
– – – – 7 809 816 (816) –
– – – – 139 (471) (222) 222 –
– – – – (33) – (33) 33 –
537 – – – – 17 554 – 554
– – – - (187) – (187) 187 –
– – – – (4) – (4) 4 –
– – – – – (42) (42) 42 –
– – – – – (66) (66) – (66)
– – – – – (228) (228) 228 –
– – – (7) (65) (1 192) (1 291) (357) (1 648)
– – – (6) (236) (315) (825) 825 –
– – – – – (361) (389) – (389)
787 82 (1 094) 940 160 (1 985) 4 207 (12) 4 195
(207) (24) 334 (149) 363 285 (987) 12 (975)
580 58 (760) 791 523 (1 700) 3 220 – 3 220
4 The banking fee and commission income consists of R272 million of revenue which passes over time while the interchange revenue of R361 million is recognised at
a point in time.
-- 23 of 58 --
22 Discovery audited results for the year ended 30 June 2022
ADDITIONAL INFORMATION
Normalised profit from operations
The following table shows the main components of the normalised profit from operations for the year ended 30 June 2022
R million
South Africa United Kingdom
June
2022
June
2021
%
Change
June
2022
June
2021
%
Change
Discovery Health 3 600 3 423 5 – – –
Discovery Life 4 028 1 341 200 – – –
Discovery Invest 1 204 1 084 11 – – –
Discovery Vitality 9 43 (79) – – –
VitalityHealth – – – 1 328 953 39
VitalityLife – – – 671 644 4
Normalised profit from established businesses 8 841 5 891 50 1 999 1 597 25
Discovery Insure (Personal lines) (162) 250 (165) – – –
Vitality Group Insurance1 – – – – – –
Ping An Health1 – – – – – –
Normalised profit/(loss) from emerging businesses2 (162) 250 (165) – – –
Discovery Bank (990) (1 094) 10 – – –
Other new initiatives1,3 (232) (288) 19 (518) (233) (122)
Normalised loss from new initiatives (1 222) (1 382) 12 (518) (233) (122)
Normalised profit from operations4 7 457 4 759 57 1 481 1 364 9
1 Included in ‘All other segments’ in the Segmental information.
2 Emerging businesses are those businesses that have achieved sufficient scale to be profitable or profitable in the near future, although not yet significant in cash
generation for the Group and likely to require funds to support new business growth.
3 Other new initiatives include costs of start-up businesses and expenses incurred to investigate, research and develop new products and markets. Start-up costs
include costs in relation to a commercial offering in Discovery Insure, an Umbrella Fund offering in Discovery Invest and the Vitality1 platform being a leading
behavioural change platform enabling shared-value insurance and financial services products across the Discovery Group. Certain unallocated heads costs
are also included in this segment. The segment also includes VitalityInvest.
4 This amount can be further analysed by referring to the Normalised profit from operations as per the Segment Total in the Segmental information.
REVIEW OF GROUP RESULTS
for the year ended 30 June 2022
-- 24 of 58 --
23
Vitality Global Total
June
2022
June
2021
%
Change
June
2022
June
2021
%
Change
– – – 3 600 3 423 5
– – – 4 028 1 341 200
– – – 1 204 1 084 11
– – – 9 43 (79)
– – – 1 328 953 39
– – – 671 644 4
– – – 10 840 7 488 45
– – – (162) 250 (165)
473 417 13 473 417 13
338 411 (18) 338 411 (18)
811 828 (2) 649 1 078 (40)
– – – (990) (1 094) 10
(365) (457) 20 (1 115) (978) (14)
(365) (457) 20 (2 105) (2 072) (2)
446 371 20 9 384 6 494 45
-- 25 of 58 --
24 Discovery audited results for the year ended 30 June 2022
ADDITIONAL INFORMATION continued
Earnings, Headline earnings and Normalised Headline Earnings
R million
Group
Year ended
June
2022
Audited
Group
Year ended
June
2021
Audited
%
Change
Earnings per share (cents):
– basic 825.5 480.7 72
– diluted 817.8 475.4 72
Headline earnings per share (cents):
– basic 792.4 454.7 74
– diluted 785.0 449.7 75
Normalised headline earnings per share (cents):
– basic 885.5 518.7 71
– diluted 877.3 512.9 71
Number of shares used in calculation
Weighted number of shares in issue ('000) 656 901 656 710
Diluted weighted number of shares ('000) 663 082 664 073
For the year ended 30 June 2022, the headline earnings and normalised headline earnings reconciliations have been amended to
enhance the presentation thereof. The presentation of the prior period has been restated accordingly to enable comparability.
HEADLINE EARNINGS RECONCILIATION
Headline earnings per share is disclosed per the JSE Listings Requirements and is calculated in accordance with the circular titled Headline
Earnings issued by SAICA, as amended from time to time. Headline earnings per share is based on the net profit after tax attributable
to ordinary shareholders adjusted for items of a capital nature and the weighted average number of ordinary shares in issue.
Group year ended
30 June 2022
Audited
Group year ended
30 June 2021
Audited
R million Gross Tax Net Gross Tax Net
%
Change
Profit attributable to the ordinary shareholders 5 422 3 157 72
Adjusted for:
– gain on disposal of intangible assets (131) 29 (102) – – –
– loss on derecognition of intangible assets 37 (5) 32 39 (8) 31
– loss on derecognition of property and equipment 13 (1) 12 11 (2) 9
– loss/(gain) on disposal of property and equipment 3 – 3 (3) 1 (2)
– impairment of intangible assets – – – 44 (3) 41
– impairment of property and equipment – – – 17 (2) 15
– adjustments attributable to equity-accounted
investments:
– gain on dilution and disposal of equity-accounted
investments (33) 4 (29) (554) 140 (414)
– (reversal of impairment)/impairment of equity-
accounted investments1 (134) – (134) 149 – 149
Headline earnings 5 204 2 986 74
1 impairment reversal was supported by a firm offer to purchase the equity-accounted investment and a change in intention resulting in reclassification
of the investments as held for sale.
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
-- 26 of 58 --
25
ADDITIONAL INFORMATION continued
Earnings, Headline earnings and Normalised Headline Earnings continued
NORMALISED HEADLINE EARNINGS RECONCILIATION
Normalised headline earnings is calculated per Discovery's policy as set out in the Accounting Policies at the end of the results
announcement.
Group year ended
30 June 2022
Audited
Group year ended
30 June 2021
Audited
R million Gross Tax Net Gross Tax Net
%
Change
Headline earnings 5 204 2 986 74
Adjusted for:
Economic assumption adjustments net of
discretionary margins and interest rate derivatives 84 (74) 10 519 (136) 383
– gain on economic assumption adjustments net
of discretionary margins (169) (26) (195) (790) 112 (678)
– loss on fair value changes on VitalityLife interest
rate derivative, excl time value of swaption 253 (48) 205 1 309 (248) 1 061
Loss/(gain) on fair value changes in the time value
of swaption contract in VitalityLife 454 (87) 367 (139) 26 (113)
Other 233 2 235 407 (257) 150
– amortisation of intangible assets arising
from business combinations 59 (13) 46 66 (13) 53
– gain on disposal of intangible asset1 131 (29) 102 – – –
– recognition of deferred tax assets on assessed
losses not recognised in previous periods – (14) (14) – (152) (152)
– loss/(gain) on fair value changes on foreign
exchange contracts not designated as hedges 2 (1) 1 304 (85) 219
– restructuring costs – – – 33 (6) 27
– transaction costs related to the VitalityLife
interest rate derivative – – – 4 (1) 3
– increase or decrease in deferred tax balances
resulting from use of different tax rates on items
that were excluded from normalised headline
earnings – 59 59 – – –
– adjustment attributable to equity-accounted
investments: amortisation of intangible assets
arising from business combinations 41 – 41 – – –
Normalised headline earnings 5 816 3 406 71
1 Gain realised from the delivery of intellectual property to Amplify Health. (Refer to ‘Other significant items in these results’ for more details.)
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
-- 27 of 58 --
26 Discovery audited results for the year ended 30 June 2022
OTHER SIGNIFICANT ITEMS IN THESE RESULTS
Provision and reserves for expected COVID-19 impact
At 30 June 2021, Discovery had reserved R3.1 billion, for both future claims and lapses as a result of the COVID-19 pandemic. This
estimation reflected management’s best estimate of the impact as at 30 June 2021 and comprised of provisions in Discovery Life
and VitalityLife and unearned premium reserves in VitalityHealth. Due to the utilisation of the available discretionary margin, some
of these provisions were accounted for against the discretionary margins in accordance with IFRS and Discovery’s accounting policy,
while the remainder was recognised in profit or loss in prior years.
Although the allowance for the COVID-19 impact was an abnormal provision for future impacts, it was not excluded in the
presentation of normalised headline earnings because it was seen as part of the core operations and will impact future cashflows.
COVID-19 is expected to transition into an endemic phase considering high immunity of the population in the Discovery client base.
Given this transition, the impact on financial metrics is expected to be less material compared to the early waves of the COVID-19
pandemic. Allowance for the remaining short-term and long-term impacts has been incorporated into business as usual reserving
for insurance contracts.
The movement in the COVID-19 provision and reserves for the year ended 30 June 2022 is as follows:
R million
June
2022
June
2021
At beginning of the period 3 080 3 442
– Provisions 2 800 2 729
– Unearned premium reserve 280 713
Movements:
– Unwinding, utilisation and release of provisions (2 798) (1 886)
– Provisions made during the period, including in respect of new business - 2 177
– Net movement in unearned premium reserve (280) (433)
– Other (2) (220)
At end of the period – 3 080
– Provisions – 2 800
– Unearned premium reserve – 280
Amplify Health
On 15 February 2022, it was announced that Discovery and AIA Group Limited ("AIA") have reached agreement to establish a new
health InsurTech business, named "Amplify Health" in which Discovery owns a 25% equity interest. The partnership will operate as
a joint venture ("JV") in certain defined parts of Asia.
Amplify Health’s vision is to be Asia’s leading digital health technology and integrated solutions business, transforming how
individuals, corporates, payors and providers experience and manage health insurance and healthcare delivery, improving the
health and wellness outcomes of patients and communities across Asia. The JV combines Discovery and AIA’s distinctive and
complementary strengths, bringing together Discovery’s market-proven health insurance technology systems and assets and its
Vitality technology platform and assets with AIA’s market-leading businesses, brand, distribution platform and decades of well-
established execution capabilities across Asia.
Subsequent to the announcement and prior to the financial year-end, the transaction agreements were finalised and Amplify
Health commenced initial activities. The impact on the results of the Group for the year under review consists of recognition of
income on delivery of an initial component of certain intellectual property by Vitality Global into the Amplify Health arrangement
amounting to R131 million, expensing of initial legal and related set-up costs of R109 million as well as immaterial equity-accounted
losses and revenue for services.
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
-- 28 of 58 --
27
Ping An Health capital contribution
As announced in the 30 June 2021 and 31 December 2021 results announcements, the Group contributed R1.5 billion additional
capital to Ping An Health during the year under review. This capital contribution represents the Group’s proportionate contribution
in respect of its 24.99% shareholding and the combined additional capital should be sufficient to support the business growth and
regulatory requirements for the foreseeable future.
VitalityInvest
As explained in the commentary to these results, a strategic review of new initiatives led to a decision to change the strategy with
regard to VitalityInvest in the UK and to effectively exit the business. This resulted in accelerated write-off of various capitalised
systems and intangible assets as well as assets arising from insurance contracts related to that business, with a pre-tax impact of
approximately R280 million.
Derivative instruments - VitalityLife business
As previously disclosed in the financial year ended 30 June 2020, VitalityLife, as a long-term insurer in the UK, has significant
exposure to long term interest rate risk and in particular exposure to lower long term interest rates and yields. In that year,
VitalityLife implemented interest rate risk mitigation strategies to protect itself against further declines in long term interest rates
by entering into derivative contracts. This strategy continues to ensure, that the VitalityLife business operated well within its pre-
determined risk appetite.
As explained at the time, the derivative instruments comprise of an interest rate swap which swaps exposure to variable interest
rates in return for fixed interest rates originally referenced to 25 year UK swap curve. During the year under review, this has been
restructured to be referenced to the 50 year swap curve to better match the exposure. In addition, the structure also included put
swap options (payer swaptions) which were acquired to provide Discovery participation in the benefit should interest rates increase
above a certain level. These swaptions have a given exercise date and therefore are required to be replaced from time to time as
has been done in the past. During the year under review the existing swaption contract was realised and replaced with a new
extended swaption at premium of GBP14 million maturing in 2024.
Reference to UK LIfe Segmental information, set out on page 19, for the year under review, the net gain recognised in the profit or
loss amounts to R567 million, consisting of economic assumption adjustments amounting to R820 million, less net fair value losses
on interest rate derivatives of R253 million (including fair value losses on the swap contracts and intrinsic value gains of the
swaption contract). Against this net gain of R567 million within the UK Life Segmental should be seen the net fair value write-off of
the time value of the swaption contract of R454 million (largely representing the opening time value of the sold swaption contract
as at the beginning of the financial year). On this basis, the effective net gain recognised in profit or loss resulting from economic
assumptions, including all hedge impacts amounts to R113 million (2021: R31 million).
The impacts of the mark-to-market revaluation of these derivative positions at reporting date are included in profit or loss for the
reporting period. When presenting “Normalised” measures, these impacts, as well as any impact recognised through profit or loss
resulting from economic assumption changes net of discretionary margins, are excluded from “normalised” results as explained in
our policy on the presentation of normalised measures.
Claims experience from civil unrest July 2021
In compliance with JSE Listings requirements, it is confirmed that the claims arising from the July 2021 unrest in both personal lines
and business lines of Discovery Insure were fully settled from the SASRIA fund, with no loss to Discovery.
April 2022 floods in KwaZulu-Natal
In compliance with the JSE Listings requirements, we report that Discovery Insure received gross claims from policyholders in excess
of R150 million in respect of personal line clients and R47 million in respect of business insurance as a result of the KwaZulu-Natal
floods in April 2022. The net impact on profit or loss after allowing for reinsurance recoveries and reinstatement premiums was
R78 million.
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
-- 29 of 58 --
28 Discovery audited results for the year ended 30 June 2022
OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
Borrowings at amortised cost
R million Reference
June
2022
June
2021
Borrowing from banks and listed debt 16 308 15 230
– United Kingdom borrowings I. 3 122 3 764
– South African borrowings II. 13 186 11 466
Bank overdraft in underlying liabilities of consolidated Unit Trusts 156 –
Lease liabilities 4 120 4 263
– 1 Discovery Place 3 373 3 388
– Other lease liabilities 747 875
Total borrowings at amortised cost 20 584 19 493
I. UNITED KINGDOM BORROWINGS
Facility
amount
GBP million Variable rate 1 Capital repayment and maturity date
Carrying value
GBP (Rand) million
June
2022
June
2021
GBP R GBP R
80 SONIA + 2.73%2 Instalments – 31 July 2023 42 847 73 1 435
34 SONIA + 1.31% 2,3 At maturity – 19 October 2022 14 276 26 512
100 SONIA + 2.38%2 At maturity – 31 July 2023 100 1 999 89 1 817
214 156 3 122 188 3 764
1 SONIA – Daily Sterling Overnight Index Average, which has replaced Libor as part of Interest Rate reform in the United Kingdom.
2 Interest payable quarterly in arrears.
3 This is a revolving credit facility.
Total finance cost in respect of the UK borrowings for the year ended 30 June 2022 was GBP 2.9 million (R59 million) (2021: GBP 4.6 million
(R95 million)).
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
-- 30 of 58 --
29
OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
Borrowings at amortised cost continued
II. SOUTH AFRICAN BORROWINGS
CREDIT RATING
In April 2022 Moody’s Investors Service (“Moody’s”) reaffirmed Discovery Limited’s Global scale long-term issuer rating of Ba3 and the
national scale long- term issuer rating at A1.za. The outlook changed to stable from negative, aligned to the outlook of the country.
DISCOVERY LIMITED
Facility
mount
R million Variable rate
Interest rate
per annum
Capital repayment and
maturity date
Carrying value
R million
June
2022
June
2021
Listed DMTN4
500 3-month Jibar + 161 bps 9.71% 1,3 At maturity – 21 November 2022 503 503
500 3-month Jibar + 205 bps 6.30%1,3 At maturity – 21 August 2023 503 503
200 – 10.46%2 At maturity – 21 November 2024 202 202
800 3-month Jibar + 191 bps 10.31% 1,3 At maturity – 21 November 2024 805 804
1 200 3-month Jibar + 191 bps 9.21%1,3 At maturity – 21 November 2024 1 217 1 220
700 3-month Jibar + 180 bps 10.29%1,3 At maturity – 21 August 2026 704 703
300 3-month Jibar + 180 bps 9.40%1,3 At maturity – 21 November 2026 303 302
792 3-month Jibar + 173 bps – At maturity – 21 May 2027 792 –
226 3-month Jibar + 180 bps – At maturity – 21 May 2029 226 –
Unlisted DMTN4, 5
1 100 – 8.92%3 At maturity – 10 March 2023 1 104 1 103
2 500 – 9.62%3 At maturity – 22 February 2025 2 520 2 519
Other
1 000 3-month Jibar + 245 bps 10.28%1,3 At maturity – 2 March 2023 1 003 999
500 3-month Jibar + 86 bps 5.85% At maturity – 30 June 2022 – 659
1 400 3-month Jibar + 125bps3 – At maturity – 12 October 2022 702 –
11 718 10 584 9 517
1 The interest rate has been fixed through interest rate swaps.
2 Interest is payable semi-annually in arrears.
3 Interest payable quarterly in arrears.
4 DMTN refers to the R10 billion Discovery Domestic Medium Term Note (DMTN) program registered in 2017.
5 During the financial year ended 30 June 2020, Discovery Limited refinanced R3.6 billion bank syndicated loans through the issue of unlisted DMTN notes.
The notes, although underwritten by a bank until maturity, are structured to enable short-term issuances into the commercial paper market on an
ongoing basis.
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
-- 31 of 58 --
30 Discovery audited results for the year ended 30 June 2022
OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
BORROWINGS AT AMORTISED COST continued
DISCOVERY CENTRAL SERVICES
Facility
mount
R million
Interest rate
per annum Capital repayment and maturity date
Carrying value
R million
June
2022
June
2021
1 400 10.60%1 At maturity – 20 December 2023 1 417 1 423
650 11.56%2 Various – final 29 October 2027 494 526
691 3-month Jibar + 1.9% At maturity – 30 June 2027 691 –
1 500 3-month Jibar + 1.45% At maturity – 8 June 2024 – –
4 241 2 602 1 949
1 Interest payable quarterly in arrears.
2 Instalments of interest and capital is monthly.
Total finance costs in respect of South African borrowings and related hedges for the year ended 30 June 2022 was R932 million
(2021: R872 million).
CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS
The Group’s capitals is defined as capital and reserves attributable to shareholders as presented on the consolidated statement of
financial position. The Group’s objectives when managing capital are:
❚ To comply with the statutory capital requirements required by the regulators of the insurance markets where the Group
operates (refer to Capital section of the directors’ report for the statutory capital requirements).
❚ To maintain a capital buffer in excess of the statutory capital requirements in order to reduce the risk of breaching the statutory
requirement in the event of deviations from the main assumptions affecting the Group’s insurance businesses.
❚ To ensure that sufficient capital is available to fund the Group’s working capital and strategic capital requirements.
❚ To achieve an optimal and efficient capital funding profile; and
❚ To consider capital management needs both in the short-term and over a five-year planning horizon.
Discovery has a Finance and Capital Committee that ensures alignment in strategic financial management between the centre and
subsidiaries within South Africa, UK and US. The committee is the governance body for all capital allocation activities across the Group.
A range of capital raising options are available to manage the capital structure of the Group, which includes the issue of new shares,
debt, reinsurance arrangements and other hybrid instruments.
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
-- 32 of 58 --
31
OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS continued
FINANCIAL LEVERAGE RATIO
As part of the capital management process, the Group monitors its capital structure utilising the Financial Leverage Ratio ("FLR").
This ratio is calculated as total debt 1 divided by total debt plus total equity. The Group’s strategy is to maintain a prudent FLR of 28%
per the Group Risk Appetite statement. However, the 28% is merely a risk appetite indicator, and does not necessarily indicate any
form of a breach in terms of regulatory or covenant restrictions. The table below summarises the FLR as at 30 June.
R million
June
2022
June
2021
– Borrowings at amortised cost 16 464 15 230
– Guaranteed deposit facilities 300 800
Total debt and guarantees 16 764 16 030
Total equity 53 555 46 419
Financial leverage ratio % 23.8% 25.7%
1 Excluding all IFRS 16 lease liabilities of R4 120 million (June 2021: R4 263 million).
The FLR at 30 June 2022 is in line with Discovery’s risk appetite.
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
-- 33 of 58 --
32 Discovery audited results for the year ended 30 June 2022
OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS continued
CAPITAL
For Group subsidiaries that operate in the insurance and financial services sectors, the relevant regulator specifies the minimum
amount and type of capital that must be held by each of the subsidiaries in addition to their insurance liabilities. The minimum
required capital must be maintained at all times throughout the period.
With effect from 1 July 2018, the Insurance Act 18 of 2017 ("Insurance Act"), and the related Prudential Standards were implemented
in South Africa. Discovery Life and Discovery Insure are regulated under the Insurance Act, while Vitality Health and Vitality Life are
regulated under the European Solvency II regulatory regime, which was implemented from 1 January 2016.
The table below summarises the capital requirements on the statutory basis, across the Group subsidiaries, and the actual solvency
capital held in relation to this requirement.
JUNE 2022 June 2021
Statutory capital requirements Cover Statutory capital requirements Cover
Discovery Life R20 322 million 1.7 times R17 647 million 1.8 times
Discovery Insure R1 138 million 1.2 times R 1 079 million 1.8 times
Vitality Health GBP 117.2 million
(R2 344 million) 1.5 times
GBP 105.6 million
(R2 084 million) 1.6 times
Vitality Life GBP 297.1 million
(R5 943 million) 2.1 times
GBP 225.5 million
(R4 451 million) 2.4 times
PING AN HEALTH (PAH) CAPITAL
As described above, Discovery made a capital contribution of R1.5 billion to PAH in proportion to Discovery’s 24.99% shareholding.
While this has been funded in the interim by way of a bridge facility and internal resources, it had been indicated that in terms of
the capital management principles applied, such capital requirements by associates and subsidiaries are typically funded by way of
capital issuance at Discovery Limited level. Given that the final regulatory approval by the Chinese Banking and Insurance Regulatory
Commission was prolonged, the capital continues to be funded as set out above. However, it remains the intention to replace the
funding with a capital issuance of only this amount if and when markets are conducive.
PART VII TRANSFER DEFERRAL
Subsequent to the disclosure in the interim results and prior to the financial year-end, Discovery and the Prudential Assurance
Company ("PAC") have finalised the agreement to a long-term deferral of the transfer of the initial Vitality Life back-book of business
originally written on the PAC license that was to be transferred to the Vitality Life Limited license ("the Part VII transfer"). The
agreement is such that the Part VII transfer is now deferred for the long-term with options to extend further and for all intents and
purposes should be viewed as an indefinite deferral. This extension is capital efficient and has a positive effect on the Group’s long-
term funding plan, is at reduced cost beyond March 2023 (the previously intended date of transfer) and resulted in a positive impact
to the Group’s embedded value.
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
-- 34 of 58 --
33
OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS continued
DEBT COVENANTS
The following are the key debt covenant ratios and their proximity to minimum requirements as per the contractual financial covenants.
Debt covenant and explanation Minimum requirement
June
2022
June
2021
Group Debt to EBITDA Ratio:
– Group debt is contractually defined and means
the aggregate consolidated financial
indebtedness of the Group and excludes items
such as the 1 Discovery Place (1 DP) lease and
includes guarantees issued to third parties.
– EBITDA is contractually defined and specifically
includes items such as dividends from
associates, rental paid on 1DP and excludes
items deemed extraordinary, such as economic
assumption adjustments, and specified FinRe
arrangements.
Less than 2.5 times 1.83 2.31
Group financial indebtedness to embedded value
– Group financial indebtedness is as per Group
Debt in the calculation
Less than 30% of Group
Embedded value
20.3% 22.6%
Discovery Life Statutory Capital Requirement (SCR) SCR cover must be more than 1.1 1.74 times 1.83 times
Group embedded value Greater than R30 billion ZAR 86 258
million
ZAR 74 645
million
New business embedded value must not be
negative.
Positive value of new business for
3 consecutive 6-month periods
June 2022:
R1 124 million
Dec 2021:
R937 million
June 2021:
R946 million
June 2021:
R946 million
Dec 2020:
R945 million
June 2020:
R726 million
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
-- 35 of 58 --
34 Discovery audited results for the year ended 30 June 2022
OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
Consolidation of Discovery Unit Trusts
Unit trusts which the Group controls in terms of IFRS 10 are consolidated into Discovery’s results for accounting purposes, which
results in the recognition of the underlying assets and liabilities of each of the funds.
Assets and liabilities of these unit trusts increased by R1 883 million respectively, compared to the prior financial year, with
movements in the following line items on the Group’s Statement of Financial Position:
Changes in assets
❚ Investments at fair value through profit or loss increased by R1 687 million.
❚ Cash and cash equivalents decreased by R304 million.
❚ Insurance receivables, contract receivables and other non-financial receivables increased by R435 million.
❚ Other assets increased by R15 million.
Changes in liabilities
❚ Investment contracts at fair value through profit or loss increased by R1 933 million.
❚ Other liabilities decreased by R100 million.
As these policies are linked, the consolidation of the Discovery Unit Trusts has no impact on the net asset value for shareholders.
There are significant trade volumes in the underlying funds of Discovery Unit Trusts. The cash flow impact of the movement in
policyholder investments for the year is included in the following line items on the Group’s Statement of cash flows:
❚ Purchase of investments held to back policyholder liabilities includes cash outflows of R30 009 million.
❚ Proceeds from the disposal of investments held to back policyholder liabilities includes cash inflows of R29 661 million.
Material transactions with related parties
DISCOVERY LONG-TERM INCENTIVE PLAN TRUST
At the annual general meeting held on 28 November 2019, the shareholders approved the establishment of the Discovery Long-
Term Incentive Plan Trust (Trust) with the purpose, inter-alia, to subscribe, purchase and/or otherwise acquire and hold Discovery
ordinary shares from time to time for the benefit of the share-based payment plan for employees, in accordance with the
requirements of the Trust. During December 2021, 3 194 870 (December 2020: 7 477 865) new shares were issued by Discovery
Limited to the Trust (December 2020: representing the allocation over the prior two years) at a value of R443 million (December
2020: R907 million), with a par value of 0.01 cents per share. While held in the Trust, these shares are treated as treasury shares and
not treated as issued, for accounting purposes.
Major customers and other Discovery entities not part of Discovery Group
DISCOVERY HEALTH MEDICAL SCHEME ("DHMS")
Discovery Health administers DHMS and provides managed care services for which it charges an administration fee and a managed
healthcare fee respectively. These fees are determined on an annual basis and approved by the trustees of DHMS. The fees totalled
R6 804 million for the year ended 30 June 2022 (2021: R6 403 million). Discovery offers the members of DHMS access to the Vitality
programme.
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
-- 36 of 58 --
35
OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
Shareholder information
DIRECTORATE
Changes to the Board of Discovery Limited from 1 July 2021 to the date of this announcement are as follows:
❚ Ms M Hlahla has been appointed as an independent non-executive director with effect from 15 August 2021. Ms M Hlahla is
a member of the Audit Committee, Remuneration Committee as well as the Social and Ethics Committee. Ms Hlahla’s appointment
strengthens the independence and business skills of the Board and Committees.
❚ Ms SE De Bruyn, an independent non-executive director, retired, effective 24 November 2021. This is in line with the Company's
board's rotation and succession planning. Ms De Bruyn has served as an independent non-executive director of the Company
since 2005 and has served as the chairperson of the Remuneration Committee and as a member of the Audit Committee. Ms
De Bruyn has also retired as a non-executive director of Discovery Life Limited, Discovery Health (Pty) Ltd and Discovery Vitality
(Pty) Ltd.
❚ Dr BA Brink, an independent non-executive director, retired, effective 24 November 2021. This is in line with the Company's
board's rotation and succession planning. Dr Brink has served as an independent non-executive director of the Company since
2004 and has served as a member of the Treating Customers Fairly Sub-committee, Social and Ethics Committee as well as the
Risk and Compliance Committee. Dr Brink has also retired as a non-executive director of Discovery Health (Pty) Ltd and Discovery
Vitality (Pty) Ltd.
❚ Ms B van Kralingen has been appointed as an independent non-executive director with effect from 7 April 2022. Ms B van
Kralingen’s appointment strengthens the experience of the Board’s global business experience, technology and artificial
intelligence expertise.
❚ Ms F Khanyile, an independent non-executive director, has been appointed as Chairperson of the Remuneration Committee
following the retirement of Ms SE De Bruyn.
❚ Mr T Mboweni has been appointed as an independent non-executive director with effect from 5 May 2022. Mr Mboweni is a
member of the Risk and Compliance Committee and the Remuneration Committee as weill as a non-executive director of
Discovery Life Limited. Mr Mboweni’s appointment brings a wealth of experience in finance, economics, and business advisory
within emerging markets.
DIVIDEND AND CAPITAL
INTERIM DIVIDENDS PAID IN RESPECT OF THE 2022 FINANCIAL YEAR
The following interim dividends were paid during the current period:
❚ B preference share dividend of 355.75342 cents per share (284.60274 cents net of dividend withholding tax), paid on
14 March 2022.
❚ No ordinary share dividends were declared.
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
-- 37 of 58 --
36 Discovery audited results for the year ended 30 June 2022
OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
Shareholder information continued
FINAL DIVIDEND DECLARATION IN RESPECT OF THE 2022 FINANCIAL YEAR
B PREFERENCE SHARE CASH DIVIDEND DECLARATION:
On 1 September 2022, the directors declared a final gross cash preference share dividend of 382.26027 cents (305.80822 cents net
of dividend withholding tax) per B preference share for the period 1 January 2022 to 30 June 2022, payable from the income
reserves of the Company. A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt.
The issued preference share capital at the declaration date is 8 million B preference shares. The salient dates for the dividend will
be as follows:
Last day of trade to receive a dividend Tuesday, 20 September 2022
Shares commence trading "ex" dividend Wednesday, 21 September 2022
Record date Friday, 23 September 2022
Payment date Monday, 26 September 2022
B Preference share certificates may not be dematerialised or rematerialised between Wednesday, 21 September 2022 and Friday,
23 September 2022, both days inclusive.
ORDINARY SHARE CASH DIVIDEND DECLARATION:
Despite the Group’s robust capital position, due to the uncertainty initially caused by COVID-19 on the demographic and economic
environment in SA combined with the volatile global macro-economic environment, the Discovery Board has decided to retain its
prior stated position during the pandemic and has decided not to declare an ordinary final dividend for the year ended 30 June 2022.
The reintroduction of an ordinary dividend will be considered on an ongoing basis.
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
-- 38 of 58 --
37
OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
Accounting policies
NORMALISED HEADLINE EARNINGS
Discovery assesses its performance using Normalised Headline Earnings, an alternative non-IFRS profit measure, alongside its IFRS
profit. Management considers that Normalised Headline Earnings Per Share (NHEPS) is an appropriate alternative performance
measure to enhance the comparability and understanding of the financial performance of the Group.
Non-IFRS measures are not uniformly defined or used by all entities and may not be comparable with similarly labelled measures
and disclosures provided by other entities.
Discovery calculates headline earnings in accordance with the latest SAICA Circular ’Headline Earnings’. NHEPS is calculated by
starting with headline earnings and adjusted to exclude material items that are not considered to be part of Discovery’s normal
operations as follows:
❚ Specified once-off transactions, for example restructuring costs, initial costs related to the Prudential book transfer, transaction
costs related to interest rate derivatives and initial deferred tax assets raised on previously unrecognised assessed losses.
❚ Unusual items – Discovery considers items to be unusual when they have limited predictive value and it is reasonable that items
of a similar nature would not necessarily arise for several future annual reporting periods. These adjustments include those
gains or losses impacting profit or loss associated with changes in economic assumptions recognised in profit or loss, net of any
gains or losses on derivatives to offset such changes in economic assumptions; or
❚ Income or expenses not considered to be part of Discovery’s normal operations, for example amortisation of intangibles from
business combinations and fair value gains or losses on foreign exchange contracts not designated as hedges.
In addition, specified items may be included in NHEPS that may otherwise have been excluded if the income is considered part of
Discovery's normal operations. For example 'gains on disposal of intellectual property', if the sale arises from the monetisation of
intellectual property rights where such monetisation is considered to be a core part of the business’s operations or strategy towards
value creation.
Management is responsible for the calculation of NHEPS and determining the inclusions and exclusions in accordance with the
policy. The Discovery Limited Audit Committee reviews the normalised headline earnings for transparency and consistency.
-- 39 of 58 --
38 Discovery audited results for the year ended 30 June 2022
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2022
OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
Basis of preparation
STATEMENT OF COMPLIANCE
Discovery Limited is a company incorporated in South Africa.
The summary consolidated financial statements for the year ended 30 June 2022 consolidate the results of Discovery and its
subsidiaries (together the Group) and equity account the Group’s interest in associates and joint ventures.
The annual results comprise the condensed consolidated statement of financial position at 30 June 2022, condensed consolidated
income statement, condensed consolidated statement of other comprehensive income, condensed consolidated statement of changes
in equity and condensed consolidated statement of cash flows for the year ended 30 June 2022 and selected explanatory notes.
The summary consolidated financial results are prepared in accordance with the JSE Limited Listings and Debt Listings Requirements,
International Financial Reporting Standards (IFRS) including IAS 34 Interim Financial Reporting, the SAICA Financial Reporting Guides
as issued by the Accounting Practices Committee and Financial Pronouncements as issued by the Financial Reporting Standards
Council as well as the requirements of the South African Companies Act 71 of 2008. The accounting policies adopted are consistent
with the accounting policies applied in the prior annual financial statements.
Amendments to standards effective from 1 July 2021 do not have a material effect on the Group’s annual results. These annual
results do not include all the notes typically included in the annual financial statements and should therefore be read in conjunction
with the Group audited consolidated annual financial statements for the year ended 30 June 2022.
Audit
The summary consolidated financial statements are extracted from audited information, but are not audited. The consolidated
annual financial statements for the year ended 30 June 2022 have been audited by the Group’s independent auditors
PricewaterhouseCoopers Inc. and KPMG Inc., who expressed an unmodified opinion thereon.
The audited annual financial statements and the auditor’s report thereon are available for inspection at the Company’s registered
office, together with the financial statements identified in the respective auditor’s reports.
The directors of Discovery take full responsibility for the preparation of this report and that the financial information has been
correctly extracted from the underlying annual financial statements.
-- 40 of 58 --
39
EMBEDDED VALUE STATEMENT
for the year ended 30 June 2022
The embedded value of Discovery consists of the following components:
❚ the adjusted net worth attributed to the business at the valuation date;
❚ plus: the present value of expected future shareholder cash flows from the in-force covered business;
❚ less: the cost of required capital.
The present value of future shareholder cash flows from the in-force covered business is calculated as the value of projected future
after-tax shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate.
The required capital are the assets attributed to the covered business above the amount required to back covered business
liabilities, whose distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements.
The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the
new business written by Discovery, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses
and cost of required capital. The value of new business is calculated using the current reporting date assumptions.
The embedded value includes the insurance and administration profits of the covered business in the Discovery Limited Group.
Covered business includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery
Health (“Health”) and Discovery Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality
Group, Ping An Health, Discovery Insure, Discovery Bank, VitalityInvest and Umbrella Funds, no published value has been placed on
the current in-force business as the businesses have not yet reached suitable scale with predictable experience.
In August 2011, Discovery raised R800 million through the issue of non-cumulative, non-participating, non-convertible preference
shares. For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted net worth.
The VitalityLife embedded value has been adjusted to allow for the agreement with Prudential in May 2022 to defer the transfer of
the VitalityLife business on the Prudential licence to the Vitality Life Limited licence ("the Part VII transfer").
The 30 June 2022 embedded value results and disclosures were subjected to an external review.
-- 41 of 58 --
40 Discovery audited results for the year ended 30 June 2022
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
TABLE 1: GROUP EMBEDDED VALUE
R million
30 June
2022
30 June
2021
%
change
Shareholders’ funds 53 555 46 419 15
Adjustment to shareholders’ funds from published basis1 (39 764) (34 184) 16
Adjusted net worth2 13 791 12 235 13
Value of in-force covered business before cost of required capital 76 077 67 175 13
Cost of required capital (3 610) (4 765) 24
Discovery Limited embedded value 86 258 74 645 16
Number of shares (millions) 657.0 656.8
Embedded value per share R131.29 R113.65 16
Diluted number of shares (millions) 668.3 665.1
Diluted embedded value per share3 R129.07 R112.23 15
1 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted using the
closing exchange rate of R20.00/GBP (June 2021: R19.74/GBP).
R million
30 June
2022
30 June
2021
Life net assets under insurance contracts (24 793) (20 675)
Vitality Life Limited net assets under insurance contracts (8 608) (7 703)
VitalityHealth financial reinsurance asset (3 021) (2 353)
VitalityHealth and Vitality Health Insurance Limited deferred acquisition costs (net of deferred tax) (450) (407)
VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) (11) (12)
Goodwill relating to the acquisition of Standard Life Healthcare and the Prudential joint venture (2 475) (2 442)
Intangible assets (net of deferred tax) in covered businesses (864) (830)
Net preference share capital (779) (779)
Reversal of 1 Discovery Place IAS 17 financial lease accounting 1 170 975
Equity settled share based payment provision adjustment 67 42
(39 764) (34 184)
For the prior period, the “Vitality Life Limited net assets under insurance contracts” included an adjustment for the Discovery funded VitalityLife business
on the Prudential licence net assets under insurance contracts. From 30 June 2022, the Discovery funded VitalityLife business on the Prudential licence
net assets under insurance contracts are no longer eliminated in the embedded value because the Discovery funding was settled as part of the agreement
to delay the Part VII transfer in the period, aligning the financial operation of all VitalityLife business on the Prudential licence.
The “equity settled share based payment provision adjustment” reflects the difference between the provision in the IFRS equity and the mark-to-market
value of the equity settled share based payments.
-- 42 of 58 --
41
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
2 The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the
embedded value:
R million
30 June
2022
30 June
2021
Shareholders’ funds 53 555 46 419
Adjustment to shareholders' funds (39 764) (34 184)
Adjusted net worth 13 791 12 235
Excess of available capital over adjusted net worth 35 342 30 718
Available capital 49 133 42 953
Required capital 39 318 32 699
Excess available capital 9 815 10 254
The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth and the available capital. This includes:
◼ The net preference share capital of R779 million which is included as available capital.
◼ The difference between Vitality Life Limited’s Solvency II Pillar 1 Own Funds and its adjusted net worth. For the prior period, this also adds back the
negative reserves eliminated on the Discovery funded VitalityLife business on the Prudential licence.
◼ The difference between Life’s Pillar 1 Own Funds and its adjusted net worth.
The following table sets out the required capital for each of the covered businesses:
R million
30 June
2022
30 June
2021
Health and Vitality 1 000 973
Life and Invest 25 403 22 059
VitalityHealth 3 164 2 847
VitalityLife 9 751 6 820
Total required capital 39 318 32 699
◼ For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost.
◼ For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement.
◼ For VitalityHealth, the required capital amount was set equal to 1.35 times the Solvency II Pillar 1 Solvency Capital Requirement.
◼ For the VitalityLife business on the Prudential licence, the required capital was set equal to 1.5 times the UK Solvency I long-term insurance capital
requirement as per the agreement with Prudential following the long-term delay of the Part VII transfer. For the business sold on the Vitality Life
Limited licence, the required capital was set equal to 1.4 times the Solvency II Pillar 1 Solvency Capital Requirement.
3 The diluted embedded value per share adjusts for treasury shares held in the Discovery BEE Share Trust and as part of Discovery’s Long-term Incentive
Plan where the impact is dilutive.
-- 43 of 58 --
42 Discovery audited results for the year ended 30 June 2022
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
TABLE 2: VALUE OF IN-FORCE COVERED BUSINESS
R million
Value before cost
of required capital
Cost of required
capital
Value after cost
of required capital
at 30 June 2022
Health and Vitality 24 528 (479) 24 049
Life and Invest1 32 073 (1 509) 30 564
VitalityHealth 2 10 658 (583) 10 075
VitalityLife2 8 818 (1 039) 7 779
Total 76 077 (3 610) 72 467
at 30 June 2021
Health and Vitality 22 503 (422) 22 081
Life and Invest1 27 777 (1 183) 26 594
VitalityHealth2 8 230 (462) 7 768
VitalityLife2 8 665 (2 698) 5 967
Total 67 175 (4 765) 62 410
1 Included in the Life and Invest value of in-force covered business is R1 734 million (June 2021: R1 675 million) in respect of investment management
services provided on off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth.
2 The value of in-force has been converted using the closing exchange rate of R20.00/GBP (June 2021: R19.74/GBP).
TABLE 3: GROUP EMBEDDED VALUE EARNINGS
R million
30 June
2022
30 June
2021
Embedded value at end of period 86 258 74 645
Less: embedded value at beginning of period (74 645) (70 834)
Increase in embedded value 11 613 3 811
Net change in capital1 (10) (7)
Dividends paid 56 63
Transfer to hedging reserve (309) (260)
Employee share option schemes (326) (330)
Embedded value earnings 11 024 3 277
Annualised return on opening embedded value 14.8% 4.6%
1 The net change in capital reflects share issues (net of costs and proceeds) and an increase (decrease) in treasury shares in the period.
-- 44 of 58 --
43
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
TABLE 4: COMPONENTS OF GROUP EMBEDDED VALUE EARNINGS
Net
worth
Cost of
required
capital
Value of
in-force
covered
business
Year ended
30 June
2022
Year ended
30 June
2021
R million
Embedded
value
Embedded
value
Total profit from new business (at point of sale) (4 657) (309) 7 027 2 061 1 891
Profit from existing business
◼ Expected return 4 317 148 2 334 6 799 6 421
◼ Change in methodology and assumptions1 3 093 1 480 (3 706) 867 (5 556)
◼ Experience variances 202 (102) 3 024 3 124 4 917
Impairment, amortisation and fair value adjustment2 (52) – – (52) (14)
Increase in goodwill and intangibles (418) – – (418) (336)
Other initiative costs 3 (860) – 24 (836) (288)
Non-recurring expenses (130) – – (130) (85)
Acquisition costs4 (41) – – (41) (40)
Finance costs (2 318) – – (2 318) (2 104)
Foreign exchange rate movements5 1 034 (62) 199 1 171 (2 316)
Other6 (16) – – (16) (8)
Return on shareholders' funds7 813 – – 813 795
Embedded value earnings 967 1 155 8 902 11 024 3 277
1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the
operating and economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to previous
embedded value statements).
2 This item reflects the amortisation of the intangible assets reflecting the banking costs, Cambridge Mobile Telematics system spend and capital expenditure
in VitalityInvest and Discovery Group Europe Limited. The prior period comparatives include the amortisation of the intangible asset raised under the
PrimeMed acquisition, which has since been dissolved.
3 This item includes the profits of non-covered businesses (including Discovery Insure, Vitality Group and Ping An Health) and costs of start-up businesses
(including Discovery Bank, VitalityInvest, a commercial offering in Discovery Insure, and an Umbrella Fund offering in Invest). Head office costs which
relate to non-covered business are also included in this item.
4 Acquisition costs relate to commission paid on the Life and Invest business and expenses incurred in writing Health and Vitality business that has been
written over the period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the value
of new business and therefore the costs are not deducted from the value of new business.
5 This item includes foreign exchange gains / (losses) emerging through the income statement, in addition to translation impacts on the cost of required
capital and value of in-force.
6 This item includes, among other items, the tax benefits or losses that will emerge as the VitalityHealth DAC and intangible software assets amortise or
increase.
7 The return on shareholders’ funds is shown net of tax and management charges.
-- 45 of 58 --
44 Discovery audited results for the year ended 30 June 2022
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
TABLE 5: EXPERIENCE VARIANCES
Health and Vitality Life and Invest VitalityHealth VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force Total
Renewal expenses 218 – (3) 2 (239) – (22) – (44)
Lapses and surrenders1 18 235 (123) 770 – 486 (218) 433 1 601
Mortality and morbidity2 – – (401) 49 563 – (26) – 185
Policy alterations1 – 64 (437) 426 – – 8 (2) 59
Backdated cancellations – – – – – – – – –
Premium and fee income 152 – 115 121 398 – (14) 156 928
Economic 3 – – (19) (150) – – (6) – (175)
Commission – – – – (43) – – – (43)
Tax4 47 – 353 (282) (16) – 183 – 285
Reinsurance – – – – 65 – (195) 74 (56)
Maintain modelling term5 – 298 – 98 – 76 – – 472
Vitality benefits 11 – – – – – 6 – 17
Other6 (21) (1) (4) (26) 89 – (237) 95 (105)
Total 425 596 (519) 1 008 817 562 (521) 756 3 124
1 For Life and Invest, the combined lapse and surrender experience and policy alterations experience is relative to assumptions which include an allowance
for a short-term stress previously set in response to deteriorating experience from COVID-19 related impacts. For VitalityLife, large favourable variances
from lower lapses were partially offset by lower in-period commission clawbacks.
2 The mortality and morbidity experience for Life and Invest reflects a strain mainly due to increased morbidity experience. All confirmed COVID-19 claims
were offset against the provision previously set and have been in line with expectation. For VitalityHealth, while claim incidence was at normal levels,
claims severity was lower than assumed for the period under review due predominantly to clinical risk management interventions. There continue to be
material uncertainties about future claims severity, with potential increases resulting from delayed treatments or undiagnosed disease during the
pandemic.
3 The experience for Life and Invest arises largely due to a significant fall in asset values in the Invest business close to the end of the financial period,
partially offset by higher than expected inflation related increases on premium and benefit increases in Life.
4 The tax variance arises due to the timing difference between the expected tax payments and actual payments.
5 For Health and Vitality, Life and Invest and VitalityHealth, the projection term is rebased at each year-end. Therefore, an experience variance arises
because the total term of the in-force covered business is effectively increased by twelve months.
6 The key Other experience relates to cash flow timing variances in Life and Invest, profits and losses from companies within the VitalityHealth and
VitalityLife segments which are not part of covered business, including the net impact of the VitalityLife swaption program, excluding gains or losses from
the hedge which are included in the economic assumption changes item.
-- 46 of 58 --
45
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
TABLE 6: METHODOLOGY AND ASSUMPTION CHANGES
Health and Vitality Life and Invest VitalityHealth VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force Total
Modelling changes 1 – – (26) (320) – 149 589 351 743
Expenses2 – (808) (49) (173) – – (189) (19) (1 238)
Lapses3 – 57 – (142) – 1 642 (254) 270 1 573
Mortality and morbidity4 – – – (2 192) – (254) 10 (414) (2 850)
Benefit changes – 83 – – – – – – 83
Vitality – – – – – – – – –
Tax5 – 274 (354) 594 – – – 112 626
Economic assumptions6 – 527 (31) (252) – (634) 922 (154) 378
Premium and fee income 4,7 – (314) – 1 966 – – – – 1 652
Reinsurance and financing8 – – 2 452 (2 423) – (30) 22 14 35
Other – – 1 (136) – – – – (135)
Total – (181) 1 993 (3 078) – 873 1100 160 867
1 For Life and Invest, certain corrections were made to the modelled long-term projection of fee income and interest income. For VitalityHealth, the item
includes a correction to the in-force data. For VitalityLife, the item reflects the deferral of the Part VII transfer of policies from the Prudential, which
predominately includes a reduced cost of capital.
2 For Health and Vitality and Life and Invest, the renewal expenses assumption was updated to reflect an increase in budgeted expenses.
3 For Life, a provision was raised for the expected continued pressure on policy alterations experience over the short-term. For VitalityHealth, the lapse item
reflects the increase in the annuity factor assumption. For VitalityLife, the lapse item includes a reduction in the term policy book’s lapse assumptions.
4 For Life and Invest, the combined impact of the mortality and morbidity assumption change and the premium and fee income assumption change
reflects the impact of a basis strengthening for endemic COVID-19 impacts as well as other short- and long-term experience components, partially offset
by higher future expected premiums. For VitalityHealth, this item reflects an update to the valuation assumptions for the gross margin, as well as a release
of a COVID-19 related stress provision. For VitalityLife, this item includes an increase in the term policy book’s mortality assumptions.
5 This item largely reflects the reduction of the South African corporate tax rate from 28% to 27%. For Life and Invest, this item also reflects the impact of
allocation changes between tax funds, resulting in a change in current and deferred tax items.
6 For Life and Invest and Health and Vitality, the economic assumptions item relates to the impact of updating the assumptions relative to the Johannesburg
Stock Exchange (“JSE”) nominal and real yield risk-free curves at 30 June 2022. For Life and Invest this item also includes the impact of updating exchange
rate assumptions. For VitalityLife the item includes the impact of updating the assumptions relative to the Solvency II yield curves and the IFRS interest
rates, offset by the net change in the interest rate hedge.
7 For Health and Vitality, the premium and fee income item relates to discounts offered to in-house schemes.
8 For Life and Invest, the reinsurance and financing item primarily relates to the impact of financing arrangements, where the future expected cash flows
arising from part of the negative reserves are monetised to match other positive policy liabilities.
-- 47 of 58 --
46 Discovery audited results for the year ended 30 June 2022
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
TABLE 7: EMBEDDED VALUE OF NEW BUSINESS
R million
30 June
2022
30 June
2021
%
Change
Health and Vitality
Present value of future profits from new business (at point of sale) 958 789
Cost of required capital (30) (24)
Present value of future profits from new business (at point of sale) after cost of
required capital 928 765 12
New business annualised premium income1 4 185 3 704 13
Life and Invest
Present value of future profits from new business (at point of sale)2 795 825
Cost of required capital (90) (82)
Present value of future profits from new business (at point of sale) after cost of
required capital 705 743 (5)
New business annualised premium income3 2 995 2 947 2
Annualised profit margin4 3.0% 3.0%
Annualised profit margin excluding Invest business 5.3% 5.7%
VitalityHealth 5
Present value of future profits from new business (at point of sale) 398 143
Cost of required capital (81) (61)
Present value of future profits from new business (at point of sale) after cost of
required capital 317 82 287
New business annualised premium income6 1 648 1 263 30
Annualised profit margin4 2.6% 0.9%
VitalityLife 7
Present value of future profits from new business (at point of sale) 219 396
Cost of required capital (108) (95)
Present value of future profits from new business (at point of sale) after cost of
required capital 111 301 (63)
New business annualised premium income 882 871 1
Annualised profit margin4 1.4% 4.1%
-- 48 of 58 --
47
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
1 Health new business annualised premium income is the gross contribution to the medical schemes. The new business annualised premium income shown
above excludes premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as well as premiums
in respect of new business written during the period but only activated after 30 June 2022.
The total Health and Vitality new business annualised premium income written over the period was R7 548 million (June 2021: R6 103 million).
2 Included in the Life and Invest embedded value of new business is R55 million (June 2021: R53 million) in respect of investment management services
provided on off balance sheet investment business.
Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the impact of which has
been recognised in the value of new business.
3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first premium
is due after the valuation date. Invest new business is defined as business where at least one premium has been received and which has not been refunded
after receipt. Invest new business also includes Discovery Retirement Optimiser policies to which Life and Invest became contractually bound during the
reporting period, including policies whose first premium is due after the valuation date.
The new business annualised premium income of R2 995 million (June 2021: R2 947 million) (single premium APE: R1 421 million (June 2021:
R1 490 million)) shown above excludes automatic premium increases and servicing increases in respect of existing business. The total new business
annualised premium income written over the period, including automatic premium increases of R1 801 million (June 2021: R1 414 million) and servicing
increases of R668 million (June 2021: R640 million), was R5 464 million (June 2021: R5 001 million) (single premium APE: R1 492 million (June 2021:
R1 569 million)). Single premium business is included at 10% of the value of the single premium.
Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans, are shown in Table 5 as
experience variances and not included as new business. Term extensions on existing contracts are not included as new business.
4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums.
5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation date
multiplied by the Margin multiplied by the Annuity Factor less the new business cash flows from point of sale to the valuation date. The assumptions for
the Margin and Annuity Factor are shown in Table 8.
6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised
premium income shown above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month,
as well as premiums in respect of new business written during the period but only activated after 30 June 2022.
7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies whose first
premium is due after the valuation date.
-- 49 of 58 --
48 Discovery audited results for the year ended 30 June 2022
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
BASIS OF PREPARATION
TABLE 8: EMBEDDED VALUE ECONOMIC ASSUMPTIONS
30 June
2022
30 June
2021
Beta coefficient 0.75 0.75
Equity risk premium (%) 3.5 3.5
Risk discount rate (%)
– Health and Vitality1 14.375 13.125
– Life and Invest1 14.875 13.625
– VitalityHealth 5.016 3.462
– VitalityLife 4.997 3.263
Rand / GBP exchange rate
Closing 20.00 19.74
Average 20.25 20.74
Margin over Expense inflation to derive Medical inflation (%)
South Africa 3.00 3.00
Expense inflation (%)2
South Africa – Health and Vitality 7.85 6.14
– Life and Invest 7.74 6.23
United Kingdom 3.50 2.50
Pre-tax investment return (%)
South Africa – Cash1 10.75 9.50
– Life and Invest bonds3 12.25 11.00
– Health and Vitality bonds3 11.75 10.50
– Equity1 15.75 14.50
United Kingdom – VitalityHealth risk-free rate 2.39 0.84
– VitalityLife risk–free rate 2.37 0.64
– VitalityLife IFRS interest rate 2.92 1.80
– VitalityLife investment return 2.00 1.44
Long-term corporation tax rate (%)
South Africa 27 28
United Kingdom 25 25
VitalityHealth Assumptions
– Margin (net of tax and cost of capital) (%)4 12.00 12.00
– Annuity Factor 7.00 6.18
Projection term
– Health and Vitality 20 years 20 years
– Discovery Life – VIF 40 years 40 years
– Group Life 20 years 20 years
– VitalityLife No cap No cap
– VitalityHealth5 20 years 20 years
1 Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds.
2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow weighted
average inflation is shown in the table. For the United Kingdom, the expense inflation assumption is aligned with the long-term market view of inflation.
3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown.
4 The VitalityHealth margin (net of tax and cost of capital) remains unchanged at 12.00%. The assumption change noted in Table 6 to reduce the gross
margin assumption at 30 June 2022 has been largely offset by the release of the stress provision present in the gross margin assumption at 30 June 2021.
5 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor.
-- 50 of 58 --
49
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
The Discovery Limited embedded value is calculated based on a risk discount rate using the CAPM approach with specific reference
to the Discovery beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk discount rate proxies the
result of a Weighted Average Cost of Capital approach with reference to the capital structure of the Group and the observed beta
calculated using daily returns over a long time period. The observed beta is calculated with reference to the ALSI. The assumed beta
will only change if the capital structure of the Group and / or the observed beta calculated using daily returns over a long time
period suggest the beta assumption should depart significantly from the assumption at the financial year-end. As beta values reflect
the historic performance of share prices relative to the market they may not allow fully for non-market related and non-financial
risk. Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly.
Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available,
augmented by reinsurance and industry information.
The Health and Vitality lapse assumptions were derived from the results of recent experience investigations.
The VitalityHealth assumptions were derived from internal experience.
VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery
Limited group information.
Renewal expense assumptions were based on the results of the latest expense and budget information.
The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding
expenses of an exceptional or non-recurring nature.
The South African investment return assumptions for Life, Invest, Health and Vitality were set relative to the publicly available JSE
risk-free nominal yield curve.
The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining
the net investment return assumption.
The risk-free rate assumption for VitalityHealth and VitalityLife was based on the single interest rate derived from the Prudential
Regulatory Authority yield curve. The inflation rate is consistent with the long-term market view of inflation.
From 30 June 2018, VitalityHealth calculate the value of in-force at the valuation date as the in-force written premium multiplied by
the Margin multiplied by the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed
future lapse rates and premium increases. The Margin assumption reflects profit margins after tax and Cost of Capital. The
assumptions underlying the Annuity Factor and Margin are set taking into account the current experience in the business at
different durations.
The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on
tangible assets. The Vitality Life Limited and the VitalityLife business on the Prudential licence required capital amount is assumed
to earn the investment return assumption, which is set based on the return on a portfolio of government and corporate bonds
assumed to back the required capital. The Life and Invest cost of required capital is calculated assuming shareholder cash flow is
limited to the cash flow available after having met both the required capital amount and an internally defined liquidity target capital
requirement of tangible assets.
The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”)
107: Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to
take into account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 2.
-- 51 of 58 --
50 Discovery audited results for the year ended 30 June 2022
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2022
Sensitivity to the embedded value assumptions
The risk discount rate uses the CAPM approach with specific reference to the Discovery beta coefficient. As beta values reflect the
historic performance of share prices relative to the market they may not allow fully for non-market related and non-financial risk.
Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly.
The sensitivity of the embedded value and the embedded value of new business at 30 June 2022 to changes in the risk discount rate
is included in the tables below.
For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for management
action such as risk premium increases where future experience is worse than the base assumptions.
TABLE 9: EMBEDDED VALUE SENSITIVITY
Health and Vitality
R million
Adjusted
net worth2
Value
of
in-force
Cost of
required
capital
Base 13 791 24 528 (479)
Impact of:
Risk discount rate +1% 13 791 23 170 (518)
Risk discount rate – 1% 13 791 26 029 (436)
Lapses – 10% 13 519 25 328 (502)
Interest rates – 1%1 12 588 24 451 (463)
Equity and property market value – 10% 13 797 24 528 (479)
Equity and property return +1% 13 791 24 528 (479)
Renewal expenses – 10% 13 905 27 047 (443)
Mortality and morbidity – 5% 14 039 24 528 (479)
Projection term +1 year 13 791 24 833 (484)
1 All economic assumptions were reduced by 1%.
2 The sensitivity impact on the VitalityLife net of tax change in negative reserves is included in the adjusted net worth column.
The following table shows the effect of using different assumptions on the embedded value of new business.
TABLE 10: VALUE OF NEW BUSINESS SENSITIVITY
Health and Vitality
R million
Value of
new
business
Cost of
required
capital
Base 958 (30)
Impact of:
Risk discount rate +1% 881 (33)
Risk discount rate – 1% 1 042 (28)
Lapses – 10% 1 017 (33)
Interest rates – 1%1 966 (30)
Equity and property return +1% 958 (30)
Renewal expense – 10% 1 097 (29)
Mortality and morbidity – 5% 958 (30)
Projection term +1 year 975 (31)
Acquisition costs – 10% 986 (30)
1 All economic assumptions were reduced by 1%.
-- 52 of 58 --
51
Life and Invest VitalityHealth VitalityLife
Embedded
value
%
change
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
32 073 (1 509) 10 658 (583) 8 818 (1 039) 86 258
28 971 (1 590) 10 075 (552) 8 216 (902) 80 661 (6)
35 768 (1 412) 11 303 (619) 9 501 (1 209) 92 716 7
35 174 (1 596) 11 899 (651) 9 462 (1 203) 91 430 6
32 584 (1 473) 11 303 (619) 8 875 (1 378) 85 868 –
31 466 (1 529) 10 658 (583) 8 818 (1 039) 85 637 (1)
32 487 (1 501) 10 658 (583) 8 818 (1 039) 86 680 –
32 722 (1 469) 11 435 (583) 9 024 (1 038) 90 600 5
34 309 (1 376) 12 331 (583) 9 187 (1 161) 90 795 5
32 181 (1 512) 10 757 (589) 8 818 (1 039) 86 756 1
Life and Invest VitalityHealth VitalityLife
Value of
new
business
%
change
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
795 (90) 398 (81) 219 (108) 2 061
601 (95) 293 (76) 119 (91) 1 599 (22)
1 023 (84) 514 (88) 333 (131) 2 581 25
1 013 (95) 555 (91) 328 (141) 2 553 24
801 (88) 514 (88) 241 (174) 2 142 4
824 (89) 398 (81) 219 (108) 2 091 1
846 (87) 500 (81) 258 (103) 2 401 16
899 (82) 617 (81) 257 (101) 2 437 18
802 (90) 415 (81) 219 (108) 2 101 2
949 (90) 435 (81) 360 (108) 2 421 17
-- 53 of 58 --
52 Discovery audited results for the year ended 30 June 2022
NEW BUSINESS ANNUALISED PREMIUM INCOME
for the year ended 30 June 2022
The new business annualised premium income (API) set out below provides a view of the scale of new business across all operations
of the Group and does not necessarily reflect the new business attributable to the legal entities within the Group. For instance,
Discovery Health Medical Scheme’s (DHMS) new business is attributable to the medical scheme but is under the administration and
marketing of Discovery Health which earns a fee in respect of such services.
Core new business API increased by 6% for the year ended 30 June 2022 when compared to the same period in the prior year.
R million
Group
June
2022
Unaudited
Group
June
2021
Unaudited
%
Change
Discovery Health1 7 292 6 079 20
Discovery Life 2 543 2 264 12
Discovery Invest 2 920 2 737 7
Discovery Insure 1 246 1 287 (3)
Discovery Vitality 256 24 967
VitalityHealth 1 738 1 367 27
VitalityLife 1 256 1 141 10
Ping An Health (24.99% interest)2 2 883 3 396 (15)
Other new business3 1 576 2 114 (25)
Core new business API of group 21 710 20 409 6
New Closed Schemes – 374 (100)
New business API of Group including New Closed Schemes 21 710 20 783 4
Gross revenue Vitality Group4 1 398 1 270 10
Combined total 23 108 22 053 5
1 New business API for Discovery Health includes new business API for all businesses administered by Discovery Health, including DHMS, Closed Schemes
and offerings such as GAP cover and Primary Care cover. The new business API for New Closed Schemes includes contracted new business API and
business in the first twelve months of on-boarding. Closed Schemes refer to those restricted to certain employers and industries.
2 Given the restructuring of the co-operation with Ping An Life for business written in certain regions in China as part of the overall re-alignment of PAH to
focus on growing high- quality own business, the core new business API measure reported for PAH sales for the year ended 30 June 2021 has been
restated to R3 396 million from R3 938 million to reflect this re-alignment..
3 Other new businesses include the Umbrella Fund, Discovery Insure commercial and VitalityInvest
4 Vitality Group new business includes gross recurring and lump sum revenues earned by Vitality Group and specifically excludes revenue related to cost
recoveries and rewards.
Calculation of New business API
New business API is calculated at 12 times the monthly premium for new recurring premium policies and 10% of the value of new
single premium policies It also includes both automatic premium increases and servicing increases on existing long-term insurance
policies. The amounts exclude indirect taxes.
The new business API in the table above differs from the new business API disclosed in the embedded value largely as a results of:
❚ The timing of inclusion of the policyholders in the calculation of new business API - in the embedded value, new business is
included from the earlier of the date that the first premium has been received or when the policy is on risk, whereas in table
above, new business is included when the policy has been contractually committed.
❚ Inclusion of automatic premium increases and servicing increases on existing life policies – these are included in the table above
but excluded in the embedded value API values disclosed.
Refer to the footnotes to Table 7: Embedded Value of New Business for a more detailed description of the differences in new
business disclosures between the embedded value and the table above.
APPENDIX A
-- 54 of 58 --
53
GROSS INFLOWS UNDER MANAGEMENT
for the year ended 30 June 2022
Gross inflows under management measures the total funds collected by Discovery. Gross inflows under management increased by
5% for the year ended 30 June 2022 when compared to the same period in the prior year.
R million
Group
June
2022
Unaudited
Group
June
2021
Unaudited
%
Change
Discovery Health 97 190 90 651 7
Discovery Life 15 053 13 714 10
Discovery Invest 24 581 24 203 2
Discovery Insure 4 672 4 107 14
Discovery Vitality 2 338 2 295 2
VitalityHealth 11 753 11 403 3
VitalityLife 6 977 6 696 4
All other business 9 604 8 974 7
Gross inflows under management 172 168 162 043 6
Less collected on behalf of third parties (95 098) (88 827) 7
Discovery Health (87 850) (81 849) 7
Discovery Invest (7 248) (6 978) 4
Gross income of Group per segmental information 77 070 73 216 5
Gross income is made up as follows:
– Insurance premium revenue 59 470 56 812 5
– Fee income from administration business 12 764 11 711 9
– Vitality Income 3 495 3 340 5
– Other income 1 341 1 353 (1)
Gross income of Group per segmental information 77 070 73 216 5
-- 55 of 58 --
Transfer secretaries Computershare Investor Services Pty Limited
(Registration number: 2004/003647/07)
Rosebank Towers, 15 Biermann Avenue, Rosebank 2196
Private Bag X9000, Saxonwold, 2132
Sponsors and debt sponsors Rand Merchant Bank (A division of FirstRand Bank Limited)
Secretary and registered office NN Mbongo, Discovery Limited
(Incorporated in the Republic of South Africa)
(Registration number: 1999/007789/06)
Company tax reference number: 9652/003/71/7
JSE share code: DSY ISIN: ZAE000022331
JSE share code: DSBP ISIN: ZAE000158564
JSE company code: DSYI
1 Discovery Place, Sandton 2146 PO Box 786722, Sandton 2146
Tel: (011) 529 2888 Fax: (011) 539 8003
Directors ME Tucker (UK) (Chairperson), A Gore* (Group Chief Executive), HL Bosman, Dr BA Brink1
, SE de Bruyn1
,
R Farber, WM Hlahla2, HD Kallner*, FN Khanyile, NS Koopowitz*, D Macready, Dr TV Maphai, T Mboweni4 ,
Dr A Ntsaluba*, A Pollard*, M Schreuder, B Swartzberg*, B van Kralingen3, DM Viljoen* (Financial Director), SV Zilwa
* Executive.
1 Retired effective 24 November 2021.
2 Appointed effective 15 August 2021.
3 Appointed effective 7 April 2022.
4 Appointed effective 5 May 2022.
Debt officer DM Viljoen
Annual financial results
– supervised by DM Viljoen CA(SA)
Embedded value statement
– prepared by P Bolink FASSA
– supervised by A Rayner FASSA, FIA
54 Discovery audited results for the year ended 30 June 2022
-- 56 of 58 --
55
-- 57 of 58 --
Discovery
+27 11 529 2888 | askthecfo@discovery.co.za | www.discovery.co.za
Subsidiaries of Discovery Limited are authorised financial services providers.
-- 58 of 58 --